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1 Introduction 
1.1 Pancreatic Ductal Adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent type of pancreatic 
tumors. It is an extremely aggressive disease with diagnosis at advanced stages and highly 
refractory to most treatments. By 2030 it will become the second leading cause of cancer 
death in developed countries (1).  
1.1.1 Epidemiology and biological features 
Pancreatic cancer is a disease of the elderly, the median age at diagnosis is 71 years 
and it is more frequent in men (1). PDAC is associated with a very poor prognosis, with 
a 5-year survival rate of only 6% and a median survival of less than 6 months (2). This 
low survival rate is the result of its aggressive features and its late diagnosis due to the 
lack of early symptoms and early biomarkers. Therefore, at the time of detection 80% of 
patients have locally advanced or metastatic PDAC and less than 20% of the patients are 
eligible for resection. Moreover, PDAC biology contributes to early recurrence, distant 
metastasis and resistance to chemotherapy and radiotherapy (3). A very important player 
in this poor prognosis is the extensive stromal reaction (desmoplasia) resulting in a 
hypovascular and hypoxic microenvironment and evasion of tumor immunity (4).  
1.1.2 Histopathology and molecular characterization of PDAC 
1.1.2.1 Histopathology 
PDAC commonly arises and progresses through a multistep process of well-defined 
and non-invasive precursor lesions that gradually accumulate mutations in oncogenes and 
tumor suppressors (5) (Fig 1). Histological and clinical studies identified distinct types of 
precursor lesions, being the most frequent, the pancreatic intraepithelial neoplasia 
(PanIN) (6). PanIN lesions can be classified into four grades based on the degree of 
dysplasia: PanIN1A (flat) and PanIN1B (papillary type) are low-grade lesions with 
minimal cytological and architectural atypia; PanIN2, a high-grade lesion with frequent 
papillary structure and nuclear pleomorphia, crowding, and hyperchromasia; and PanIN3 
(or in situ carcinoma) characterized by severe cytological and architectural atypia with 
papillary morphology. All grade PanINs are non-invasive lesions that do not invade the 
basement membrane (5, 7).  
DOI:10.14753/SE.2018.2172
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Figure 1. Multistep pancreatic carcinogenesis. (Upper) Scheme of step-wise genetic 
alterations followed by histological transformation. Mutation in the K-Ras oncogene 
initiating ductal reprogramming and transformation into PanIN1A/B low grade lesions. 
Accumulation of subsequent mutations in tumor suppressors, such as INK4A (PanIN2); 
and P53 and SMAD4 (PanIN3) results in high grade lesions and finally to PDAC 
formation. (Lower) H&E staining of histological alterations during pancreatic tumor 
development and CK19 IHC of PDAC (adapted from Neesse et al., 2015; and Barbacid, 
2013). 
PanIN lesions develop through a reprogramming process (transdifferentiation), 
known as acinar-to-ductal metaplasia (ADM), which is frequently associated with 
atrophy of acinar parenchyma and activation of the K-RAS oncogene as initiating steps 
(6). Molecular analyses have demonstrated that PanINs harbor many of the genetic 
alterations found in PDACs (8). Early events include mutations in K-RAS and CDKN2A 
as well as telomere shortening providing an environment that is permissive to acquisition 
of chromosomal rearrangements and preceding mutations in P53 and SMAD4, tumor 
suppressors that are found lost in high grade lesions (PanIN3) (Fig 1) (8).  
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1.1.2.2 Molecular genetics of pancreatic ductal adenocarcinoma  
More than 90% of PDACs harbor mutations in the K-RAS oncogene, detected 
already in early PanIN lesions (8, 9). Therefore, it is considered the initial driver mutation.  
The K-RAS oncogene: K-RAS is a member of the RAS family of GTP-binding 
proteins that mediate different cellular functions: proliferation, differentiation, and 
survival (10). In pancreatic cancer, oncogenic mutations in the K-RAS locus cluster in hot 
spots, more frequently in codon 12 (11, 12). This results in inhibition of GTP hydrolysis 
activity that leads to constant activation of the protein and finally aberrant cell 
proliferation (13). The most common mutations are G12D (44%), followed by G12V 
(30%) and G12R (20%), respectively. The latter was present with high prevalence in 
samples with multiple K-RAS mutations suggesting distinct signaling properties of this 
allele (9). In addition, PDACs with wild-type K-RAS have activating mutations in 
members of the MAPK pathway (9). Oncogenic mutations in BRAF, such as V600E, can 
be found in 3% of PDAC samples (14) and are mutually exclusive with K-RAS mutations 
(15). Interestingly, a subset of K-RAS wild-type PDACs display elevated activation of 
MTOR pathway, converting it into a therapeutic target for these patients (9). 
CDKN2A: The most frequent allelic losses in PDAC affects the locus that encodes 
the cyclin-dependent kinase CDKN2A/p16 tumor suppressor that inhibits cell cycle 
progression (16). Deletion, mutation or promoter hypermethylation of 9q21 locus occurs 
in 80–95% of low-grade PanINs (17, 18). This locus encodes two overlapping tumor 
suppressors - INK4A and ARF, and their respective protein products P16INK4A and P14ARF 
(19). INK4A inhibits CDK4/6-mediated phosphorylation of RB, thereby blocking the cell 
cycle; ARF stabilizes P53 by inhibiting its MDM2-dependent proteolysis. Cooperation 
of K-RAS and INK4A mutation was postulated in several studies (20) given their mutual 
genetic alteration during early steps of pancreatic carcinogenesis. 
P53: Inactivating missense mutations in the DNA binding domain of P53 are 
frequently found in PDAC patients (50-70%) (17). These genetic alterations appear in 
later stages of PanIN formation, in an established environment of genomic instability and 
ROS induced DNA damage response (20). Interestingly, loss of function of ARF and P53 
coexist in 40% of human PDAC (18). 
SMAD4: sporadic loss of function of SMAD4/DPC transcriptional regulator by 
deletion or intragenic point mutations takes place in 50% of human PDACs (21). As a 
central component of TGF-ß signaling, SMAD4 mutations appear at late stages of 
pancreatic tumorigenesis (22).  
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1.1.2.3 Signaling pathways activated in PDAC 
1.1.2.3.1 RAS – MAPK  
In addition to the role of K-RAS mutations in PDAC initiation, constitutive RAS 
signaling has been described to be required for PDAC maintenance (2, 23). Three RAS 
genes encode four RAS isoforms (H-RAS, N-RAS and K-RAS4A and K-RAS4B), with 
the splice variant K-RAS4B being the main isoform expressed in human cells (24) and 
tumors (25). Upon extracellular stimuli RAS proteins activate numerous downstream 
signaling pathways including the MAPK signaling, a key pathway that controls essential 
cellular processes, such as proliferation, survival and differentiation (10). This pathway 
includes a family of serine/threonine kinases (RAF/MEK/ERK), that through 
phosphorylation events result in a proliferative phenotype in many cells (26). RAS-GTP 
binds to RAF proteins (A-RAF, B-RAF, C-RAF), initiating a signaling cascade and 
activates MEK1/2, which phosphorylates ERK1/2 kinases. The latter has more than 150 
substrates in the cytosol and in the nucleus, most of them involved in cell proliferation 
(27).  
RAS can also activate the PI3K signaling pathway, which is an essential regulator 
of cell survival (28) via AKT, p70-S6K, and PDK-1 downstream effectors (29). This 
pathway is constitutively active in most pancreatic cancers. Moreover, mutations in the 
catalytic subunit of PI3K (p110α, encoded by PI3KCA) and amplification of AKT are 
commonly found in human PDACs, however mutations in its endogenous inhibitor, 
PTEN, are uncommon (15). The importance of this pathway in pancreatic tumorigenesis 
was shown by activating the p110α subunit of PI3K in K-Ras driven mouse model 
resulting in PDAC promotion (30, 31), whilst PDK-1 ablation abrogated tumor 
development (31).  
1.1.2.3.2 Growth factor signaling  
PDAC shows increased expression of Epidermal Growth Factor Receptors (EGFR 
and ERBB2) and their ligands (TGF and EGF), consistent with the presence of an 
autocrine loop (32). Importantly, EGFR inhibitors decrease PDAC cell growth and 
tumorigenesis in vitro (33), as well as inhibit growth of orthotopic tumors in combination 
with cytotoxic chemotherapy (34). In 2007, a clinical trial in phase III showed a limited 
benefit in survival of PDAC patients with the combination of gemcitabine and the EGFR 
inhibitor Erlotinib, compared with the treatment with gemcitabine only (35).  
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Other important growth factors, such as the Insulin Growth Factor (IGF), regulate 
survival, invasion, and angiogenesis of many human cancers. PDACs show elevated 
expression of IGF-I in both the tumor and stromal compartment, as well as aberrant 
activation of the IGF-I receptor (IGF-IR) in tumor cells (36). In PDAC patients, IGF1R 
overexpression was associated with decreased survival (37). Increased levels of IGF 
binding proteins (IGFBPs) are found in PDAC (38), however, low expression of IGFBP3 
and IGFBP7 has been correlated with poor clinical outcome (39). IGFBP-s are reservoirs 
of circulating IGFs but also regulate cell growth and survival (40), although their 
complete function is not well understood.  
Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) 
signaling appears to contribute to mitogenesis and angiogenesis of PDAC (41). 
Overexpression of FGF receptors has been detected in pancreatic tumors (42), where 
elevated bFGF levels contributed to the PDAC desmoplasia (43). VEGF promotes 
endothelial cell proliferation and survival by binding to the VEGFR-1 and VEGFR-2 
transmembrane receptors (44). VEGF is overexpressed by PDAC cells (45), whereas 
disruption of VEGF signaling strongly suppresses tumor growth of pancreatic cancer 
xenografts (46).  
1.1.2.4 Stroma modulating pathways in PDAC  
1.1.2.4.1 Hedgehog signaling 
The Sonic Hedgehog family is comprised of secreted signaling proteins that 
regulate the growth of many organs, including the pancreas during embryogenesis (47). 
Hedgehog ligands, such as SHH, disrupt inhibition of SMO and activate the GLI 
transcription factor. SHH is activated in PanINs and neoplastic cells (48), yet, the activity 
of GLI in PDAC is restricted to the stromal compartment (49). Pharmacological inhibition 
of Shh signaling in PDAC GEMMs resulted in reduced stroma, increased vessel density 
and enhanced drug delivery (50). However, genetic deletion of Shh in mouse tumor cells 
recapitulated stroma reduction but resulted in aggressive, undifferentiated tumors (51). 
This is in line with another study demonstrating that Shh activation provokes stromal 
hyperplasia and reduced growth of epithelial compartment (52).  
 TGF-ß signaling 
TGF-ß belongs to a superfamily of secreted proteins, whose other members include 
growth factors (BMPs, Activins) that activate SMAD proteins and regulate proliferation, 
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differentiation, as well as migration. More importantly, TGF-ß promotes transformation 
and proliferation of fibroblasts and controls the process of epithelial mesenchymal 
transition (EMT) in tumors (53).  
In pancreatic cancer, more than 50% of the tumors show inactivation of SMAD4 
(6). In tumor cells TGFß regulates EMT process downregulating the activity of Snail and 
Zeb-1 transcription factors (54). Moreover, TGFß regulates PDAC stroma as a major 
factor of fibrosis via the secretion of several pro-tumorigenic growth factors including 
VEGF and CTGF, as well as MMP2 and MMP9 (55). In addition, it suppresses 
inflammatory processes through inhibition of cytotoxic T-cells, macrophages and NK 
cells (56). 
1.1.2.4.3 IL – 6/JAK-STAT pathway 
The Signal Transducer and Activator of Transcription (STAT) family of 
transcription factors are phosphorylated by Janus Kinases (JAK) tyrosine kinases (57, 
58). They regulate numerous cellular processes including self-renewal, proliferation and 
inflammatory pathways (59).  
In human PDAC, frequency of STAT3 alteration ranges between 30-100% (60) and 
correlates with decreased survival  (61). Moreover, STAT3 is not essential for normal 
pancreatic homeostasis (62) but is involved in all stages of pancreatic tumorigenesis (63, 
64) Recent studies have demonstrated that IL6 cytokine-induced activation of STAT3 is 
responsible for remodeling the desmoplastic PDAC stroma and for immune surveillance 
(61, 65). In addition, IL6 secreted by stromal cells also induced Stat3/Socs3 expression 
via IL6 trans-signaling and accelerated PDAC progression in mouse models (66).  
1.1.2.4.4 NF-B pathway 
Nuclear factor kappa B (NF-B) signaling might be another downstream mediator 
of the mutated RAS pathway in pancreatic cancer. Its activation occurs in response to 
cellular stress through pro-inflammatory cytokines and growth factors resulting in 
regulation of immune response and apoptosis (67, 68). A link between K-RAS and NF-
B signaling through pP62 was reported to drive tumor initiation and progression in 
PDAC (69). Moreover, NF-B connects inflammation and cancer by recruitment of 
inflammatory cells and activation of cytokines. Cross activation of TGF-ß and IL-1ß 
signaling via NFB further contributes to the generation of complex inflammatory PDAC 
stroma (70).  
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1.1.2.5 Molecular subtypes of PDAC  
In 2011, an analysis based on gene expression data of primary tumors and tumor 
cell lines correlated with clinical outcome and response treatment identified three 
molecular subtypes of PDAC: classical, quasimesenchymal (QM) and exocrine-like 
tumors. Classical subtype was characterized by overexpression of adhesion-related and 
epithelial genes, such as GATA6. QM tumors had high expression of mesenchymal-
associated genes and these patients showed the worst median survival. Exocrine-like 
PDAC genes were enriched in digestive enzyme genes (71). Interestingly, QM PDAC 
cells were more sensitive to gemcitabine than the Classical subtype. Conversely, the latter 
responded better to Erlotinib suggesting treatment specificity.  
In 2015, virtual microdissection of gene expression in PDAC samples by non-
negative matrix factorization identified two tumor-specific subtypes: classical (more 
differentiated tumors associated with GATA6 expression and characterized by 
significantly higher SMAD4 expression) and basal [tumors with significantly worse 
median survival and faster growth rate in PDX (Patient Derived Xenografts) (72)].  
In 2016, a study based on integrated genomic analysis of 456 PDACs defined 4 
molecular subtypes: squamous, pancreatic progenitor, aberrantly differentiated 
endocrine exocrine (ADEX) and immunogenic (73). Squamous tumors, presented poor 
prognosis and were associated with mutations in P53. EGF signaling and upregulated 
TP63DN transcriptional network were found activated, whereas genes involved in 
pancreatic cell differentiation (ie: Pancreatic and Duodenal Homeobox 1 (PDX1), 
GATA6) were downregulated (73). Pancreatic progenitor tumors overexpressed genes 
involved in early pancreatic development like FOXA2, FOXA 3 and PDX1 among others 
(73). Immunogenic tumors appeared similar to the pancreatic progenitor subtype, but with 
a significant increase in immune cell infiltrates. These tumors exhibited overexpression 
of immune network pathways, including CD4+ and CD8+ T cell and Toll-like receptor 
signaling (73). ADEX tumors showed deregulation of pathways involved in late stages of 
pancreatic development. They were characterized by upregulating genes associated with  
K-RAS activation and transcriptional networks related to acinar and endocrine 
differentiation (73).  
Finally, recent findings showed integrated molecular analysis and classification of 
150 primary tumor samples from the TCGA database. Whole exome sequencing, mRNA 
and protein profiling provided a complex molecular landscape of PDACs. The above 
classifications were applied on the TCGA PDAC data set and the analysis found an 
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overlapping between basal – like (Moffitt et al.) and squamous tumor (Bailey et al.) 
subtypes, enriched in P53 mutations. Likewise, classical and pancreatic progenitor 
subtypes of PDAC were confirmed across platforms and were associated with increased 
GNAS mutations (9).  
1.1.2.6 Molecular subtypes of PDAC stroma 
Interestingly, the study of Moffitt et al. described PDACs with two distinct stroma 
subtypes: ‘activated and normal’ (Fig 2). Additionally, this study identified a cluster of 
samples with low or missing stroma (‘low stroma’). Patients with ‘activated’ stroma had 
significantly worse median survival than patients with ‘normal’ stroma (Fig 2) (72). 
Normal stroma was characterized by high expression of the well-established 
myofibroblast marker SMA (alpha-smooth muscle actin), Vimentin and Desmin. 
Activated stroma was characterized by a diverse inflammatory signature of macrophage 
related chemokines (CCLs) and integrins, as well as other tumor promoting factors like 
SPARC, members of the Wnt pathway, collagens and matrix metalloproteinases (MMPs) 
(72). 
 
 
Figure 2. Stroma subtypes of PDAC in the virtual microdissection study of Moffitt 
et al. (Left) Heat map of primary tumor samples separated based on transcriptome profiles 
and matrix factorization. Samples clustered into three groups, describing samples with 
activated stroma, samples with normal stroma and samples with low or absent stromal 
gene expression. (Right) Kaplan-Meier survival analysis of patients with resected PDAC 
from the activated and normal stromal clusters shows that samples in the activated stroma 
group have worse prognosis (P = 0.019) (adapted from Moffitt et al., 2015).  
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Taken together, identification of tumor and stroma specific molecular signatures suggests 
an important interaction between tumor compartments to be considered in the future for 
tumor characterization and for stroma and immune modulating therapies.  
1.1.3 Therapeutic approaches to treat pancreatic cancer 
1.1.3.1 Conventional chemotherapies and standard of care treatments 
One of the reasons of the poor overall survival (OS) rates of pancreatic cancer is 
the lack of efficient therapies. Despite of the progress already achieved among 
gastrointestinal malignancies, there have been modest advances in the treatment of 
pancreatic ductal adenocarcinoma (74, 75). In 1996, Gemcitabine was approved by the 
FDA for treatment of pancreatic cancer. This was further confirmed by a randomized 
clinical trial showing a significant improvement in the OS of gemcitabine versus 5-
fluorouracil (76). A decade later Erlotinib (EGFR inhibitor) in combination with 
Gemcitabine was approved for treating metastastic PDAC. However, the survival 
improvement was marginal (0.4 month) (35). Other combinations of cytotoxic agents or 
targeted therapies failed to achieve survival benefit or presented increased toxicity. 
Indeed, first-line therapy FOLFIRINOX, a combination of leucovorin, 5-fluorouracil, 
irinotecan and oxaliplatin, showed significant advantage versus Gemcitabine (11.1 vs. 6.8 
months), but only for patients with good performance (77). The other important advance 
was a clinical trial in 2013 with the combination of gemcitabine plus nab-paclitaxel (the 
nanoparticle albumin-bound formulation of paclitaxel) and since then, it became the 
standard of care treatment. Yet, the improvement in survival remains low compared to 
Gemcitabine alone (8.5 months vs. 6.7 months, respectively) (76), which highlights the 
urgency for developing new and more effective therapeutic strategies. 
1.1.3.2 Molecular targeted therapies – clinical trials 
In addition to the aforementioned novel front-line treatments, many others 
possibilities are under investigation. It is expected that molecular targeted therapies, 
monoclonal antibodies and immunologic activation will add survival benefit and will 
increase life quality of PDAC patients.  
Direct pharmacologic inhibition of K-RAS has been unsuccessful in the past 
decades due to its high binding affinity to GTP and the inability to identify an easily 
accessible active site. Studies are ongoing to find alternative approaches, still with limited 
success (78). Targeting of the downstream RAF/MEK/ERK signaling pathway by MEK 
inhibition resulted in PI3K mediated reactivation of EGFR (79). PDAC cells also 
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overexpress IGF-1R, although its inhibition with ganitumab combined with gemcitabine 
in a Phase III randomized controlled trial did not show improvement and the study 
finished earlier (80).  
Targeting JAK/STAT signaling by ruxolitinib in combination with capecitabine 
(precursor of the 5-fluorouracil) showed improved OS in patients with high C reactive 
protein levels in a Phase II trial (81). Phase II trial is currently ongoing to evaluate 
ruxolitinib in metastatic PDAC (ClinicalTrials.gov identifiers: NCT02119663 and 
NCT02117479). In addition, inhibitors of TGF-ß, WNT and NOTCH signaling pathways 
based on preclinical studies are under clinical testing (82). 
1.1.3.3 Immune therapies – clinical trials 
Different strategies have been addressed to harness the host’s immune system 
against PDAC (82). For instance, by using vaccines such as the Mesothelin specific CD8+ 
T cell that improved overall survival (83). Immunotherapy by immune checkpoint 
inhibitors (i.e., CTLA-4, PD-1, PD-L1 and others) inhibitors offers encouraging results 
in preclinical models but often fails to show clear benefits in clinical trials for PDAC. 
The monoclonal antibody anti-CTLA4 Ipilimumab was ineffective in PDAC (84). 
However, its combination with a GM-CSF secreting PDA vaccine (GVAX) resulted in 
synergistic effects and raised OS (85). Clinical trial of PD-L1 inhibition with the 
monoclonal antibody BMS-936559 was sadly unsuccessful in PDAC (86). Yet, in 
preclinical studies combination with the CXCR4 inhibitor, AMD3100, the treatment 
induced tumor regression (87, 88). Currently, combination of Ulocuplumab (anti-
CXCR4) and Nivolumab (anti-PD1) is in a phaseⅠstudy (NCT02472977) (82). 
 
1.1.4 Mouse models to study pancreatic cancer 
Genetically engineered mouse models (GEMMs) that recapitulate the human 
disease are important tools to understand PDAC biology and to design novel therapeutic 
approaches (89). Homologous recombinant technology on ES cells and the use of Cre and 
Flp recombinases allows a fine-tuned control of genetic alterations in a time- and tissue-
specific manner.  
1.1.4.1 K-Ras induced mouse models 
Remarkable efforts have been made to generate GEMMs that recapitulate the full 
spectrum of histological alterations found in human patients. Since transformation of K-
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RAS is considered to be the initiating genetic event in PDAC tumorigenesis, most of the 
models involve endogenous expression the K-RAS oncogene. The first model that 
fulfilled the above criteria included the conditional expression of a mutant K-RasLSLG12D 
allele controlled by the expression of the Cre recombinase in early embryonic 
development under the Pdx1 or P48 pancreatic lineage specific promoters (Pdx1-Cre; K-
RasLSLG12D, referred as “KC”) (90).  
Our laboratory generated a bitransgenic strain (Elas-tTA/tetO-Cre) that allows the 
control of the K-Ras oncogene expression by a tet-off strategy: the expression of the Cre 
recombinase is controlled by the acinar cell specific Elastase promoter that controls the 
expression of a tetracycline trans-activator and the expression of the Cre recombinase is 
under the control of a Tet operon. These mice were crossed with the K-RasLSLG12Vgeo 
conditional knock-in mice (91). In the absence of doxycycline, this compound strain (K-
RasLSLG12Vgeo; Elas-tTA/tetO-Cre) expresses the K-Ras oncogene and the -
Galactosidase reporter in a 20-30% of acinar cells from E16.5 of embryo development 
(92). These mice recapitulate the human disease, develop the full spectrum of PanIN 
lesions and a small proportion develop PDAC. Surprisingly, when mice are treated with 
doxycycline until the age of 8 weeks and the K-Ras oncogene is expressed in adult acinar 
cells no neoplastic growth occurs in the pancreas unless these mice undergo chronic 
pancreatitis (92). 
The low frequency of malignant transformation suggested the need of additional 
genetic events that occur in later stages of PDAC development, such as mutations in 
tumor suppressors (p16Ink4a/p19Arf and p53) (6, 93). p53 inactivation, either by a 
conditional knock-in mutant (p53R172H) (K-RasLSLG12D;p53R172H; Pdx1-Cre, referred as 
“KPC”) or by p53 conditional null alleles (K-RasLSLG12Vgeo;p53lox/lox;Elas-tTA/tetO-
Cre, in this study referred as “KPeC”) results in accelerated tumor progression and 
generation of invasive lesions with complete penetrance (94). In addition, a percentage 
of these mice also develop metastatic tumors (89). Inactivation of p16Ink4a/p19Arf 
results in 100% penetrance of PDAC and decreases tumor latency in mice.  
Numerous mouse models were generated and characterized with additional genetic 
alterations known to play a role in PDAC development. Modifications in Smad4, 
Ink4/Arf, or elimination of Lkb1 and Tgfbr2, Notch1 acted as tumor suppressors and 
accelerated PDAC formation. On the other hand, Egfr was shown to be essential for 
pancreatic tumor development by two independent groups including our laboratory (95, 
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96). Many of them target all cell types of the pancreas (acinar, ductal and endocrine), and 
are expressed at early embryonic stages. Therefore, these studies only represent 
preventive strategies.  
To perform real therapeutic trials new mouse models have been developed that 
allow the elimination of the target in established lesions. These models utilize a dual 
recombinase system (DRS) (Cre-LoxP, Flp-FRT), where tumors are induced by K-Ras in 
cells expressing Flp recombinase driven by Pdx1, along with the ablation of the p53 tumor 
suppressor gene (p53Frt) during embryonic development. When the tumor is developed, 
secondary modifications can be obtained in targets flanked by loxP sites by tamoxifen 
induced Cre recombination. On the other hand, expression of the Cre recombinase, can 
be also controlled by a stromal lineage specific promoter (i.e. fibroblasts) (97).  
In parallel, our laboratory has generated a “therapeutic strain” using the same 
approach. These animals express the Flp recombinase in Elastase positive cells during 
late embryonic development leading to the expression of the resident K-RasG12V oncogene 
and to the ablation of the p53 tumor suppressor gene. When the tumor is developed, 
tamoxifen induced elimination of Egfr or C-Raf targets occur ubiquitously in cells 
expressing the Cre-recombinase driven by the human Ubiquitin C promoter (Blasco et al. 
unpublished).  
These new models will help not only to target tumor cells, but also other cell types 
in the tumor microenvironment. This will greatly contribute to better understanding of 
tumor – stroma interactions and to develop novel combinatory therapeutic approaches. 
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1.2 Tumor microenvironment  
Cancers are heterogeneous cellular entities, whose growth not only depends on 
tumor cells that harbor driver mutations of oncogenes and loss of tumor suppressors, but 
also on interactions with the dynamic microenvironment (stroma) co-evolved during 
tumor development (98).  
1.2.1 Distinct cell types of the tumor microenvironment 
The tumor microenvironment (TME) is constituted by a diverse population of 
activated and/or recruited cell types by cancer cell and cancer stem cells (CSCs), such as 
cancer associated fibroblasts (CAFs), innate and adaptive immune cells, endothelial and 
other cell types that form blood and lymphatic vessels. Interaction between cancer cells 
and the closed normal tissue, as well as the components of the stroma regulates and define 
the aspect of tumorigenesis (Fig 3) (99).  
 
Figure 3. Distinct cells types of the tumor microenvironment (TME) in solid tumors. 
Subtypes of the stromal cells, such as inflammatory cells can include both tumor-
promoting as well as tumor-killing subclasses either they belong to adaptive (T cells, B 
cells, natural killer (NK) cells) or innate immune (tumor associated macrophages 
(TAMs), myeloid derived suppressor cells (MDSCs)) response. Cell types including 
cancer associated fibroblasts (CAFs), endothelial cells, mesenchymal stem cells (MSCs) 
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are depicted. Cancer cells and cancer stem cells (CSCs) orchestrating the recruitment of 
the TME, while invasive cancer cells break away from primary tumor sites. 
1.2.1.1 Immune cells - immunosurveillance 
A functional link between inflammation and cancer is well accepted. Patients 
suffering from chronic inflammation are more prone to develop tumors due to the pro-
growth environment of the inflammatory cells (98). However, the immune system plays 
dual role in tumor development by either tumor inhibition or support (100).  
1.2.1.1.1 Innate immune cells  
Components of the innate immunity, including macrophages, dendritic cells, mast 
cells, granulocytes or myeloid-derived suppressor cells (MDSCs) are recruited by growth 
factors, such as TGF-ß, VEGF or colony-stimulating factor-1 (CSF-1) and chemokines 
(CCL2, CCL5, etc.). These inflammatory cells release mediators that contribute to tumor 
growth, invasion and metastasis (101). 
Tumor associated macrophages (TAMs), with similar characteristics as of M2 polarized 
(anti-inflammatory) macrophages, produce factors (101), that can directly affect cancer 
growth and metastatic dissemination by establishing pre-metastatic niches (102, 103). 
Furthermore, TAMs are also responsible for therapeutic resistance by antagonizing 
antitumor activity of treatments or by regulating T-cell activation (104).  
MDSCs are a heterogeneous population of immature myeloid cells recruited from bone-
marrow (105), and have strong immunosuppressive activities such as the regulation of T 
and NK cells anti-tumor activity and stimulation of regulatory T cells (106).  
1.2.1.1.2 Adaptive immune cells  
A typical solid tumor will contain all adaptive immune cell-types (natural killer 
(NK) cells, B and T cells), mainly located in the surrounding layer. Mature T cells are 
divided into two major groups based on the T cell receptors (TCRs) and are further 
classified according to the effector functions as CD8+ cytotoxic T cells (CTLs) and CD4+ 
helper T (Th) cells, which include Th1, Th2, Th17, and T regulatory (Treg) cells, as well 
as natural killer T (NKT) cells (107). The process of activating cytotoxic CD8+ T cells 
and/or DC4+ T helper cells can be skewed in different ways, e.g. by cancer cells 
reprogramming the protective immune response, termed immunosurveillance (108). 
Increased numbers of T cells usually are correlated with better prognosis in several 
cancer types, including melanoma, colon and pancreatic cancer (108). The ratio of CD8+ 
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CTLs and Treg cells indicates the balance between host defense or tumor promotion 
(109). Treg cells mostly suppress antitumor immune responses (110), whilst NK cells and 
CTLs perform cytotoxic immunity (111). Recently, programmed death-ligand 1 (PD-L1) 
overexpressed by various tumor cell types, and its receptor (PD-1) on T cells became an 
important target. In several tumors refractory to conventional chemotherapy anti-PD-
1/PD-L1 succeeded, such as in melanoma (112). Yet, a group of solid cancers remain 
unresponsive (86).  
1.2.1.2 Endothelial cells – angiogenesis  
For the rapid expansion of a primary tumor, oxygen and nutrition supplies are 
needed. This requires the generation of new blood vasculature by activation of quiescent 
vessels (angiogenesis) (113). However, tumors develop irregular and dysfunctional new 
vessels (114), very often via overexpression of VEGF growth factor.  
Endothelial cells can be activated by cytokines (bFGF, TNF-α, TGF-ß, PDGFs, 
PIGF and Neuropilin-1), chemokines (CXCL12, IL8/CXCL8), matrix metalloproteinases 
(MMPs), ROS and bioactive mediators, such as nitric oxide (NO) (115). Angiogenesis 
can be regulated by tumor associated macrophages (TAMs) through direct VEGF-A 
production (116) or via MMP9 secretion, which releases VEGF-A from the extracellular 
matrix  (ECM) (117). Blockade of TAM secreted CSF-1 resulted in vascular 
normalization and improved therapeutic response (118). In addition, neutrophils were 
also reported to promote angiogenesis by MMP9 production (119), as well as cancer 
associated fibroblasts (CAFs) through pro-angiogenic signaling factors (120).  
1.2.1.3 Extracellular Matrix 
The tridimensional organization of the TME is highly dynamic and is dependent of 
the extracellular matrix (ECM) surrounding the cells. The ECM contains a mixture of 
fibrillar proteins, glycoproteins, proteoglycans, cytokines and growth factors (121), 
which supports cell adhesion via binding cell surface adhesion receptors and integrin 
signaling (122). Physical features of the ECM include its porosity and rigidity, spatial 
arrangement and orientation of insoluble components, as well as other features that 
together determine its role supporting tissue architecture. 
Abnormal ECM and increase in collagen deposition can result in tumor stiffness 
and upregulation of integrin signaling, thus promoting cell survival and proliferation  
(123). Additional components, such as Hyaluronic acid also defines the structure and 
physical properties of the stroma (124). In addition, aberrant regulation of the ECM may 
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convert a normal stem cell niche into a cancer stem cell niche, disrupt tissue polarity and 
integrity to promote invasion (125). Importantly, in the periphery of benign tumors, 
enhanced collagen synthesis results in tight encapsulation of the tumor (126), suggesting 
that initial stromal responses may retain neoplastic expansion. However, reprogramming 
of the stroma by cancer cell directs them towards malignant progression (98).  
1.2.1.4 Cancer Associated Fibroblasts (CAFs)  
Fibroblasts are important and abundant cells in any context. They survive severe 
stress that is usually lethal to all other cells and are essential in tissue homeostasis, wound 
healing and repair processes in response to exposure to chemicals or carcinogens (127). 
Indeed, there is an increasing body of evidence of their role in tumor development, in 
agreement with the hypothesis of Dvorak stating “cancer is a wound that never heals” 
(128).  
1.2.1.4.1 Origins of CAFs 
In tissue repair, fibroblasts proliferate and differentiate into myofibroblasts, along 
with the expression alpha-smooth muscle actin (α-SMA), collagen, fibronectin, and other 
fibrillar proteins resulting in a reactive desmoplastic stroma (129). Aberrant regulation of 
the constitutive wound healing process leads to the generation of malignant stromal tissue 
and diverse fibroblast populations. In the process of tumorigenesis, they are collectively 
designated as cancer associated fibroblasts (CAFs). 
CAFs are a heterogeneous cell population (Fig 4) derived from multiple origins, 
such as bone marrow, adipose tissue, mesenchymal stem cells (MSCs), epithelial and 
cancer cells through EMT process, endothelial cells via endothelial mesenchymal 
transition (EndMT) or mainly from adjacent normal tissue fibroblasts (130). They are 
defined by elongated, spindle-like morphology and by expression of distinct markers, 
characterizing each subtype (127). They are found in many solid cancers, however, 
abundance of CAFs is a typical feature of prostate, breast and pancreatic cancer (131).  
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Figure 4. Origins of CAFs. Bone marrow derived cells (BMDCs) including fibrocyte 
precursors and mesenchymal stem cells (MSCs) contribute to the diverse CAF 
population, as well as epithelial, cancer and endothelial cells via EMT or EndMT process. 
The majority of CAFs is derived from tissue resident fibroblasts. 
1.2.1.4.2 Molecular markers  
The molecular characterization of CAFs has illustrated that there is no unique 
marker to label all CAFs and that most markers are not even specific to CAFs or 
fibroblasts. While αSMA is used as a robust CAF marker, which usually identifies CAFs 
with myofibroblast morphology (132),  it is also expressed by normal fibroblasts (133) 
and in some cases at comparable or even higher level (134, 135). FSP1 or S1004A is 
another marker of CAFs, even though it seems to have a differing role in cancer (136). 
Another well described marker is the cell surface serine protease fibroblast activation 
protein (FAP) (137). Further overexpression among cell surface proteins include the 
neural marker, NG2 and PDGFRß, that is also found on vascular cells (138). Interestingly, 
PDGFRß activation was also reported in invasive pancreatic tumor cells (139).  
Finally, it was reported in different cancer types, such as skin and pancreatic tumors 
that PDGFRα is a marker of a CAF population characterized by pro-inflammatory gene 
signature (140). However, it also labels immune, adipose and mesenchymal stem cells; 
and drives adipose tissue derived fibrosis (141, 142). Of note, PDGFRα could be 
considered as EMT marker in tumor cells (143). 
1.2.1.4.1 Functional properties of CAFs 
Each of CAF subtypes can contribute to a variety of tumor-promoting functions in 
different organ-specific TMEs (Fig 5). For example, CAFs are a source of paracrine 
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signaling molecules that include mitogenic epithelial growth factors, hepatocyte growth 
factor (HGF), EGF family members, insulin-like growth factor-1 (IGF-1), stromal cell-
derived factor-1 (SDF-1/CXCL12), and a variety of FGFs and VEGFs, with the capability 
to stimulate cancer cell proliferation, angiogenesis, invasion and metastasis (88, 127, 144, 
145). CAFs can also orchestrate functional attributes associated with EMT via secretion 
of TGF-ß (146). In addition, they can express a wide range of ‘‘proinflammatory’’ 
cytokines (140, 147), thereby recruiting and activating inflammatory cells, that in turn 
provide proliferative signals. Importantly, CAFs also undergo metabolic reprogramming 
by switching from oxidative phosphorylation to glycolysis via IDH3 downregulation, 
resembling a Warburg-like effect that leads to tumor growth support (148). 
Nevertheless, evidence suggests that normal connective tissue fibroblasts (but not 
CAFs) from various organs can inhibit tumor growth through a process that requires 
contact of the normal fibroblasts with cancer cells, in governing epithelial homeostasis 
and proliferative quiescence (149, 150). Therefore, normal fibroblasts could act as tumor 
suppressors, a function that is lost upon reprogramming to become CAFs. 
1.2.2 Tumor microenvironment in PDAC 
Among many epithelial tumors, pancreatic cancer displays the most extensive 
stromal reaction accounting for up to 90% of the tumor volume. This profuse 
desmoplastic stroma is characterized by CAFs and inflammatory infiltrates, as well as 
huge amount of ECM generating a rigid, impenetrable tumor tissue with high interstitial 
fluid pressure and compression of vessels (124). This reactive environment acts as a 
physical and a chemical barrier against treatments (151, 152).  
CAFs are the most abundant cell type in PDAC stroma that produce ECM 
components, such as collagens, fibronectin, laminins and hyaluronic acid, glycosamino 
glycans (GAGs) (Fig 5) (124). They also stimulate tumor cell growth by paracrine 
signaling, support migration and invasion, as well as acquired resistance mechanisms. 
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Figure 5. Histology of human and mouse PDAC. Masson’s trichrome histochemistry 
shows robust collagen deposition (blue). Pentachrome staining reveals collagen, (GAGs) 
and mucins (turquoise/green). Hyaluronic acid binding protein hybridization probe 
displayes intense HA content. αSMA immunohistochamistry shows abundant expression 
in the stroma but not in tumor cells. (Adapted from Provenzano et al. 2012.) 
The reactive fibrotic environment contributes to hypoxia and immune cell 
infiltrates. While immune cells are also plentiful within the stroma, they mostly belong 
to immunosuppressive subsets, such as regulatory T cells (Tregs), T-helper (Th cells) 
cells, TAMs and multiple subsets of immature MDSCs. TAMs support tumor progression 
and invasion by producing pro-tumorigenic factors and induce resistance to gemcitabine 
treatment by upregulating the levels of the drug metabolism related enzyme, cytidine 
deaminase, in PDAC cells (153). In a recent study, Zhu et al. identified TAMs of distinct 
origins in PDAC: tissue resident macrophages display pro-tumorigenic functions and pro-
fibrotic transcriptional signature, whilst monocyte-derived TAMs appear to play a role in 
antigen presenting (154). In contrast, CD8+ T cells are not frequent in the tumor stroma 
and when present they are located in the surrounding tumor tissue (152).  
Therefore, these findings suggest that stroma elimination could deplete the physical 
barrier and enhance drug delivery to the cancer cells located inside of the tumor mass, 
while also disrupting deleterious stroma – cancer cell interactions. Studying tumor – 
stroma interactions by GEMMs can shed light on important cellular processes and 
therapeutically targetable pathways. 
1.2.3 Cancer Associated Fibroblasts (CAFs) in PDAC 
In pancreatic cancer, a specific cell type, pancreatic stellate cells (PSC) are the 
major source of CAFs. PSCs is a specific cell type (155), that can be found in pancreas, 
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liver, kidney, lung and intestine (156) and that share many characteristics of fibroblasts. 
In normal pancreas, PSCs are in a quiescent state with a specific stellate morphology 
located in the peri-acinar space and contain lipid droplets that serve as Vitamin A storage 
(Fig 6). Various markers have been described to identify quiescent PSCs, including 
desmin, nestin, GFAP, vimentin (155, 157, 158). Upon activation, they start to express 
αSMA, change their cytoskeleton, and acquire elongated shape and myofibroblast 
phenotype. They control the ECM turnover by producing MMPs and collagens. They can 
be activated by PDGFs TGF-ß, TNF-α, and interleukins, such as IL1, IL6 and IL10. 
Indeed, PSCs associated to PDAC express receptors of these cytokines (159). This 
activation could be reversed in vitro by retinoic acid (Fig 6) (160). 
 
Figure 6. Activation of Pancreatic Stellate Cells (PSCs). Quiescent PSCs express 
Desmin, Vitamin A and GFAP; and contain lipid droplets. Upon activation by 
inflammatory cytokines, tissue injury or oxidative stress (ROS) they transform into 
myfibroblasts, change their morphology and start to express markers, such as αSMA, 
Vimentin, PDGFRs, etc. Activated PSCs can be reverted by retinoic acid. 
As described above, CAFs are key players in the TME of pancreatic cancer. Being 
the most frequent cell type in PDAC stroma (80%) they are also responsible for the 
extreme stiffness of the tumor tissue by producing insoluble fibrillary matrix components. 
This results in hypoxia and a reactive microenvironment, rich in infiltrating, suppressive 
immune cell populations, ideal for tumor progression and therapy resistance (124). 
Subpopulations of CAFs in PDAC  
CAF subpopulations can be defined by their origins or/and molecular profile (127, 
130). CAF subtypes are not well characterized, indeed, there is only minor description of 
these subpopulations in PDAC. For instance, a CD10-positive subpopulation of CAFs 
was identified in human PDAC specimens. These cells were localized juxtatumorally, in 
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the vicinity of tumor cells in patients with shorter survival (161). In a recent study, Öhlund 
at el. defined two distinct populations of CAFs showing molecular divergence. MyCAFs 
(myofibroblast CAFs), with increased expression of the well-known myofibroblast 
marker SMA, located in close proximity of neoplastic cells. iCAFs (inflammatory 
CAFs), on the other hand were localized more distant from tumor cells and displayed 
inflammatory-secretory expression profile with elevated expression levels of IL-6 but 
lacking SMA in a mutually exclusive but reversible fashion (162).  
1.2.3.1 Preclinical studies targeting CAFs in PDAC 
Targeting the pro-tumorigenic effects of CAFs in pancreatic cancer offers many 
possibilities due to their functional diversity. Indeed, several strategies have been 
suggested to obtain therapeutic benefits in PDAC (Fig 7).  
Targeting the stroma and ECM as physical or chemical barrier. The desmoplatic 
stroma in PDAC has been considered a barrier to drug delivery. Targeting the production 
of the ECM or its degradation are both feasible strategies to loosen the stroma and to 
induce expansion of blood vessels. In 2009, inhibition of the Hedgehog pathway by the 
Smo inhibitor IPI-926, was shown to be efficient to reduce stromal content, induce 
angiogenesis and improve intratumoral Gemcitabine content (151). In contrast, when Hh 
was genetically deleted in a pancreatic cancer mouse model, despite the attenuated stroma 
and an increased vascularization, these tumors appeared undifferentiated and more 
aggressive leading to reduced survival in mice (51, 52). 
High interstitial fluid pressure can be reduced by enzymatic digestion of hyaluronic acid, 
a major component of the ECM (124). Degradation of hyaluronan by the peglylated form 
of hyaluronidase (PEGPH20) normalized the hydrostatic pressure, lead to increased 
delivery of chemotherapy and prolonged survival in KPC mice (124, 163). The matrix 
protein SPARC is overexpressed in the ECM of many tumor types. nAb-Paclitaxel, an 
albumin-bound Paclitaxel, was postulated to bind to SPARC and thereby induce stromal 
depletion. This hypothesis was supported by the analysis of PDAC samples and patient-
derived xenografts (PDX) (164). However, in KPC mice stromal loss occurred rather due 
to implicated drug–drug interactions via reduction of cytidine deaminase levels (165). 
Moreover, tumor-bearing KPC mice lacking SPARC did not respond differently to nAb-
paclitaxel compared to control mice, showing the mechanism of action is independent of 
SPARC expression (166).  
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It was recently illustrated in KPC mice that CAFs can act as a chemical barrier by 
retaining gemcitabine metabolites through reduced levels of key inactivating metabolic 
enzymes compared to tumor cells. By this mechanism, CAFs limited the drug uptake of 
cancer cells (167).  
Targeting secreted factors of CAF-tumor cell interactions. Blocking the CAF-
secreted connective tissue growth factor (CTGF) resulted in a synergistic effect with 
gemcitabine without increasing the intratumoral gemcitabine concentration via 
deregulation of the apoptosis modulating protein XIAP (168).  
On the other hand, Cxcl12 secreted from FAP-positive cells was shown to be important 
for immune suppression, explaining why immune checkpoint inhibitors, such as anti-PD-
L1, have failed in pancreatic cancer (84). Notably, in KPC mice, inhibition of Cxcr4, the 
Cxcl12 receptor, promoted the intratumoral T cell recruitment and strongly cooperated 
with anti-PD-1L (137). Likewise, inhibition of Cxcr2, a receptor activated by CAF 
produced ligand Cxcl1/2 in KPC mice prolonged survival and improved T cell entry. 
Interestingly, germline elimination of Cxcr2 completely abrogated metastasis but had no 
effect on tumor development suggesting cellular context and tumor stage dependent 
action of this receptor (169).  
Targeting CAFs by reprogramming. Depletion of CAFs in a pancreatic cancer 
model led to more aggressive and less differentiated tumors (170). Thus, the protective 
role of certain stromal elements should be taken into consideration and reprogramming, 
rather than eliminating CAFs, should be considered. Reprogramming of CAF behavior to 
change their properties to a more “normal” phenotype can be achieved by multiple 
mechanisms. Since CAFs undergo metabolic changes, normalization of the metabolic 
phenotype and inhibition of metabolic pathways have also been suggested as a possible 
way to target tumors (171). 
Another approach postulated to dedifferentiate them into a quiescent state is based on 
Vitamin D since Vitamin D Receptor (VDR) ligands promoted the dedifferentiation of 
liver stellate cells and abrogated fibrosis (172). In PDAC, Vitamin-D mediated stromal 
reprogramming markedly reduced inflammation and returned PSCs into a quiescent state, 
thereby decreasing tumor volume and increasing chemotherapy efficacy (173).  
Finally, inhibition of PDGF signaling, an important pathway in the activation of CAFs, 
can reverse CAFs into normal fibroblasts (174). In PDAC, metastatic potential was 
significantly reduced upon Imatinib treatment of tumor-bearing KPC mice, while 
showing no effect on primary tumor development (139).  
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Figure 7. CAF targeting approaches. 1. Targeting the stroma as a physycal barrier :by 
Hyaluronidase  and Hedgehog inhibitors to decrease ECM and to improve drug delivery. 
2. Targeting CAF secreted factors: by inhibitors of Ctgf, Cxcl12 to block interactions 
with tumor cells. Targeting CAFs – secreted ECM mediated pro-tumorigenic effect by 
Cxcr4 inhibition. Blocking Cxcl1/2 improves intratumoral T cell entry. 3. 
Reprogramming CAFs into “normal” fibroblasts by deactivation using PDGFR inhibitors 
or VDR ligands.  
In conclusion, there is emerging evidence from preclinical studies that pro-
tumorigenic properties of CAFs represent an attractive and promising therapeutic target 
in PDAC that deserve further studies.  
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1.3 Serum Amyloid A protein family 
Serum Amyloid A (SAA) is an acute phase high-density apolipoprotein family, 
whose levels are highly increased upon inflammatory stimuli, tissue injury, trauma or 
cancer (175). Although, different pro- and anti-inflammatory properties have been 
recently connected to distinct isoforms of SAAs, their role in defense mechanisms and 
cancer development is not entirely understood.  
1.3.1 SAA functions in normal homeostasis 
SAA is a highly conserved protein family (176) suggesting evolutionary 
significance and physiological importance (177). They are considered apolipoproteins 
(proteins that bind lipids and transport them through the circulatory systems) since in the 
circulation they associate with high-density lipoproteins (HDL), such as cholesterol, 
thereby playing an important role in lipid metabolism (178). During inflammatory events, 
acute phase response is initiated to eliminate pathogens and restore normal homeostasis. 
This involves HDL remodeling, where SAA1 and SAA2 displace ApoA-1 and become 
apolipoprotein of HDL (179). It is unknown if the role of SAAs during acute 
inflammation is to raise cholesterol removal from tissue damage sites or to deliver 
cholesterol esters to cells involved in tissue repair (180). In addition, it was recently 
reported that SAAs could have functional role in retinol (Vitamin A) binding and 
transport during infection and inflammatory response (181).  
1.3.1.1 SAA family members 
In humans, four SAA encoding genes are clustered on chromosome 11 in a segment 
of 150 Kb (182). SAA1 and SAA2 are located in close proximity and contain several 
allelic variants. The third gene, SAA3 is situated further downstream of SAA4 and was 
identified as pseudogene in humans (hSAA3P) with a defective promoter generating a 
translational stop signal (183). However, mRNA transcripts were reported in mammary 
gland epithelial cells (184) and in cancer. SAA1 and SAA2 are designated as ‘acute phase 
SAA’ (A-SAA) since their serum concentration could strike to 1000-fold during 
inflammatory response, whilst SAA4 is referred as ‘constitutive SAA’ (C-SAA) secreted 
into the blood circulation constitutively by hepatocytes in ‘normal’ physiological 
conditions (185).  
In mice, as well as in humans, Saa1 and Saa2 are major acute phase proteins along 
with constitutive expression of Saa4 in liver. Nevertheless, Saa3 is secreted 
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predominantly by extrahepatic tissues, including macrophages, adipocytes and fibroblasts 
(186) associated with a wide range of inflammation related cellular functions.  
1.3.2 SAAs in disease and cancer 
1.3.2.1 SAAs as major acute phase protein and inflammatory cytokine 
Chronic inflammatory diseases, such as obesity, diabetes, rheumatoid arthritis, 
atherosclerosis and Alzheimer’s disease are associated with SAA overexpression. 
Increased levels of SAA are found in serum and synovial fluid of rheumatoid arthritis 
(RA) patients (187), as well as in synovial fibroblast, macrophages and endothelial cells 
(188). SAA is upregulated in smooth muscle cells of obese patients (189). Moreover, the 
same type of cells stimulated with recombinant Apo-SAA exhibited increased 
proliferation and migration via induction of chemokines, such as CCL2 and CXCL8, 
chemotactic agents for monocytes and neutrophils in atherosclerosis (190). Finally, SAA 
overexpression was associated with pulmonary diseases including cigarette smoke 
induced chronic lung inflammation (191), as well as with systemic inflammatory 
response upon brain injury (192). 
1.3.2.2 Regulation, receptors and signaling  
SAA transcription can be induced by cytokines, chemokines, both in autocrine or 
paracrine fashion. The strongest activators of SAA are pro-inflammatory cytokines via 
NFKB signaling, where Il-ß is the most potent SAA inducer followed by IL6 and TNF-
α, although cooperation of at least two of them is often necessary (193). On the other 
hand, SAA induces the production of these cytokines and chemokines in different cell 
types including CCL2, CXCL8 and CXCL1 in monocytes, neutrophils and fibroblasts 
(193). 
Functional receptors of SAA identified until now include the formyl peptide 
receptor 2 (FPR2), the scavenger receptor class B type I (SR-BI), the receptor for 
advanced glycation end products (RAGE), the Toll-like receptors 2 (TLR2) and 4 (TLR4) 
(180). FPR2 is the main receptor of SAA induced cytokine synthesis via NFKB and MMP 
transcription (188). In addition, chemoattractant activity of SAA via FPR2 have been 
described in monocytes, neutrophils, and T-cells (193). SR-BI, is the primary receptor for 
native HDL through binding its apolipoprotein, SAA. Native HDL promoted cellular 
cholesterol efflux was induced by SAA via SR-BI (175). RAGE activated by SAA leads 
to the stimulation of NF-κB and MAPK in rheumatoid synovial fibroblasts. TLR2/4 are 
involved in SAA induced inflammatory signaling and activation of cytokine/chemokine 
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production. Indeed, IL-6, TNF-α and IL-10 in synovial fibroblasts was stimulated through 
TLR2 (194). 
1.3.2.3 Dual role of SAA in cancer  
Increased SAA levels were reported in several type of cancers, such as gastric and 
ovarian cancer, myeloma and osteosarcoma (180) with a gradual increment between early 
and late stages suggesting involvement in tumor pathogenesis, and a potential to be a 
prognostic marker (195).  
Several studies have shown pro- and anti-tumorigenic properties. These include 
inhibition of tumor invasion by binding to ECM components, or on the contrary, 
induction of ECM degrading enzymes allowing tumor cell migration (180). Interestingly, 
such dual role of SAA was recently reported in nasopharingeal carcinoma, where opposite 
effects were associated to SAA1 SNP variants. Out of the five SAA1 polymorphic allele, 
SAA1.1 and SAA1.3 possessed anti-angiogenic properties, whereas SAA1.5 lacked 
tumor suppressive effect (196). Of note, these polymorphic variants in mice were not 
identified (197). In fibroblasts, such as hepatic stellate cells (HSCs), SAA activated IκB 
kinase, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced NF-κB. In the liver, 
SAA induced cell death upon NFKB treatment in rat HSCs, while in hepatocytes the same 
conditions promoted phosphorylation of ERK/MAPK signaling (198).   
In pancreatic cancer SAA was among the 183 overexpressed genes in tumor tissue 
compared to normal samples (199). Moreover, its plasma levels correlated with clinical 
stage in PDAC patients (200), thus it was proposed to be used as a biomarker combined 
with Haptoglobin (201). 
1.3.2.4 Functional studies of Saa3 in mice 
SAA is a family of highly homologous proteins. This similarity is even conserved 
between species. For example, the murine Saa3 and human SAA1 share 74% of their 
amino acid sequence, and 73% with the mouse Saa1 (194).  
Adipose tissue damage augmented Saa3 and hyaluronic acid levels which induced 
monocyte recruitment and retention, as well as cell adhesion leading to local 
inflammation (202). However, Saa3 is not amyloidogenic and does not contribute to 
plasma Saa levels during acute phase response (203) In MDSCs, Saa3 overexpression 
resulted in limited antitumor activity, thereby exacerbating tumor growth (204). 
Moreover, Saa3 activates p38 – MAPK and NF-B via Tlr4 (205), while it stimulates 
growth of regulatory T cells in a process involving Il-1β and Il-6 induction in monocytes 
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(206). In endothelial cells and macrophages Saa3 contributes to establishing pre-
metastatic niche (207). Indeed, involvement of Saa3 in metastatic processes was further 
confirmed by several groups (191, 208). For instance, S100A4 stimulated transcription 
of Saa1 and Saa3 through TLR4/NFKB pathway, which in turn, enhanced cell adhesion 
to fibronectin and increased tumor cell migration linking inflammation to metastasis 
promotion.  
Mice deficient in Saa3 has been generated (209). When fed with high fat diet, Saa3 
knockout mice reduced weight gain and adipose tissue inflammation. Female Saa3 null 
mice also improved plasma cholesterol, triglycerides and lipoproteins profiles compared 
to controls implicating an a significant role of Saa3 in cholestherol regulation (209).  
Taken altogether, in this thesis, I have characterized a CAF subpopulation with 
protumorigenic properties defined by the expression of the platelet-derived growth factor 
receptor alpha (PDGFRα). The comparative transcriptome analysis of fibroblasts present 
in normal pancreata showed that the most differentially overexpressed gene in CAFs was 
Saa3, a member of the acute-phase Serum Amyloid A (SAA) apolipoprotein family found 
associated with high density lipoproteins in plasma (176). Expression of SAA members 
is induced in injured tissues and cells including atherosclerotic plaques, rheumatoid 
synovitis and in certain tumor cells (180). Moreover, they are considered as biomarkers 
whose expression is associated with tumor progression and reduced survival in many 
human cancers, including PDAC (180, 210).  
We describe that Saa3 plays a key role in inducing the pro-tumorigenic properties 
of PDGFRα+ CAFs. In addition, we also specify that the pro-tumorigenic activity of Saa3 
is regulated by the Membrane Palmitoylated Protein 6 (Mpp6), a member of the 
peripheral membrane-associated guanylate kinases (MAGUK). In addition, we identified 
and functionally validated further targets differentially overexpressed in CAFs and 
generated GEMMs by CRISPR/Cas9 gene editing technology in order to study their role 
and their potential therapeutic value in PDAC development. 
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2 Objectives 
 
The following objectives were set for this thesis work: 
 
1. Comparison of the gene expression profiles of cancer associated fibroblasts 
(CAFs) in PDAC to normal pancreatic fibroblasts (NPFs) to find specific targets 
that can help to reprogram the CAFs to counteract their pro-tumorigenic 
properties. 
 
2. Functional validation of the pro-tumorigenic properties of the selected targets.  
 
3. Generation of germline knock-out alleles in PDAC mouse model to study the 
role of the selected targets in vivo in pancreatic cancer development. 
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3 Materials and Methods 
3.1 Mouse models 
3.1.1 KPeCY mouse model 
The K-Ras+/LSLG12Vgeo;Trp53lox/lox;Elas-tTA/tetO-Cre PDAC mouse strain was 
generated by crossing K-Ras+/LSLG12Vgeo (91) with the bitransgenic Elas-tTA/tetO-Cre 
strain (provided by Dr. Grippo, Northwestern University, Chicago, IL, USA and Dr. J.I 
Gordon, Washington University, St. Louis, MO, USA). The Cre recombinase expression 
is driven by the acinar cell specific Elastase promoter and is under the negative control 
of the doxycycline inducible Tet operon (Tet-off system). Trp53Lox/Lox mice were 
obtained from Anton Berns ́ laboratory (The Netherlands Cancer Institute, Amsterdam, 
The Netherlands). Rosa26+/LSLEYFP mice were obtained from The Jackson Laboratory, 
(generated by Dr. Soriano). Mice were maintained in a mixed C57BL/6 - 129/Sv 
background. 
3.1.2 Saa3 germline KO 
Saa3 null sperm (Saa3tm1(KOMP)Vlcg) was obtained from the KOMP Repository and 
used to generate Saa3 null mice by in vitro fertilization of KPeCY females at the CNIO 
Transgenic Unit. Tm1 modification was designed to replace the entire protein with a 
reporter tagged selection cassette utilizing BAC-VEC system (211). 
3.1.3 Therapeutic strain 
The K-Ras+/FSFG12V;Trp53frt/frt;Elas-tTA/tetO-FLp(o);Egfrlox/lox;c-Raflox/lox;Ub-
CreERT2 strain was generated by intercrossing. The K-Ras+/FSFG12V
  
was developed in 
Mariano Barbacid’s laboratory in CNIO (Drosten unpublished). In collaboration with the 
CNIO Transgenic Mice Unit, we generated the Elas-tTA/tetO-Flp bitransgenic strain. The 
Trp53Frt/Frt
 
was generated in David Kirsch ́s laboratory (Duke University Medical Center, 
Durham, NC, USA). The Tg.hUBC-CreERT2+/T (212) was generated in Eric. J. Brown ́s 
laboratory (University of Pennsylvania, School of Medicine, Philadelphia, PA, USA). 
The EgfrLox/Lox allele (213) was obtained from Maria Sibilia ́s laboratory (Institute for 
Cancer Research, Vienna, Austria). The c-RafLox/Lox (214) was generated in Manuela 
Baccarini ́s laboratory (Institute of Microbiology and Genetics, Vienna, Austria).  
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3.1.4 Maintenance of mice 
All mice used in these projects were housed in the Animal Facility of the Spanish 
National Cancer Research (CNIO) in accordance with Federation of European Laboratory 
Animal Science Association (FELASA) recommendations and following European 
Union legislation. All experiments described in this thesis have been approved by the 
Bioethics and Animal Welfare Committee of the Institute for Health Care Carlos III. Mice 
were subjected to light and dark cycles of 12 hours each with temperature and humidity 
regulated. Animals were fed ad libitum with a standardized diet (28018S, Tekland).  
3.1.5 Generation of mouse models by CRISPR 
3.1.5.1 sgRNA design and validation 
For each target gene, six sgRNA sequence were designed by CRISPRScan (215) 
based on their disposition in the locus and the off-target effects. Sequences were validated 
in CAF cell line by a dual lentiviral system. SgRNA sequences were cloned into a 
pLKVU6 lentiviral backbone and constitutive Cas9 expressing CAFs were infected as 
described above (see 3.2.5). Validation of mutations (indels) was performed by T7 
endonuclease assay and sequencing (see 3.3.4.3). When antibodies were available protein 
expression was validated by western blot. Most efficient sgRNA knock-down sequence 
was selected to proceed with in vivo microinjection. The following sgRNA sequences 
were used: 
Has1:  
sgRNA 5’: CACCGCGTTGGGGCGGCAAACGTGGT 
sgRNA 3’: TAAAACCACGTTTGCCGCCCCAACGC 
Lumican:  
sgRNA 5’: CACCGACACTACCGACTAATGCCAGT 
sgRNA 3’: TAAAACTGGCATTAGTCGGTAGTGTC 
Haptoglobin: 
 sgRNA 5’: CACCGAGATTGCAAACGGCTATGTGT 
 sgRNA 3’: TAAAACACATAGCCGTTTGCAATCTC 
Mesothelin:  
sgRNA 5’: CACCGCCAACAGCTCGACCCCTGCGT 
sgRNA3’: TAAAACGCAGGGGTCGAGCTGTTGGC 
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3.1.5.2 sgRNA preparation and Microinjection 
To prepare sgRNAs for microinjection T7 promoter was added by Hi Fidelity PCR 
(KAPA, HiFi Hotstart PCR Kit) amplification using Px330 as template. The following 
primers were designed for each gene: 
Forward: T7 promoter, sgRNA sequence, crRNA sequence: 
5′- TGTAATACGACTCACTATAGGNNNNNNNNNNNNNNNNNNNNgtttta
gagctagaaatagc-3′ 
Reverse: 5′-AGCACCGACTCGGTGCCACT-3′ 
The PCR reaction contained 1.5 l dNTP Mix, 10 l 5X PCR Buffer, 1.5l of each 
primer (10 M), 1 l of Px330 plasmid template, 0,5 l KAPA Hi-Fi DNA polymerase 
and 34 l sterile water. At least 8 reactions were prepared in order to obtain enough 
material for the following step. T7-sgRNA product was gel purified and used as template 
for in vitro transcription to RNA by using MEGAshortscript T7 Transcription Kit 
(Ambion). RNA was purified by MEGAclear Kit (Ambion) and quality was verified by 
Bioanalyzer. This process was performed for each target gene, as well as for Cas9.  
Microinjections were performed in collaboration with the Transgenic Mice Unit in 
CNIO. Zygotes were derived from the therapeutic strain. 30 ng/l sgRNA and 50 ngl 
Cas9 mRNA was microinjected into the cytoplasm of the one-cell state embryos. Next, 
the mouse embryos were transferred into foster mothers and chimeras were born. 
3.1.5.3 Genotyping strategy 
3.1.5.3.1 T7 endonuclease assay 
This assay detects heteroduplex DNA that results from annealing DNA stands that 
have been modified after a sgRNA/Cas9 mediated cut to DNA strands without 
modifications. PCR products amplified from each sample were purified by QIAquick Gel 
Extraction Kit. Briefly, 600 ml of QG buffer was added to the PCR product, mixed well 
and loaded on the Qiagen spin column. Samples were washed two times with 500 ml 
ethanol containing PE buffer. T7 endonuclease (NEB) was used to detect mismatched 
DNA. To do this, 200 ng of PCR product was mixed with 2 ml of NEB2 buffer and 
reaction volume was filled up to 20 ml with sterile water. Hybridization was perfomed in 
thermocycler as following: 5min, 95ºC; ramp down to 85ºC, at -2C/s; ramp down to 25ºC, 
at -0.1C/s; hold at 4ºC. 1 l of T7 endonuclease was added to each sample and incubated 
at 37ºC for 15 minutes. Reaction was directly loaded on 10% polyacrylamide gel (4 ml 
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30% Acryamide, 6,8 ml water, 2,4 ml Tris-Borate-EDTA (TBE), 200 l 10% APS, 10 l 
TEMED) to separate DNA fragments. 9 l DNA ladder was used as standard. 
Electrophoresis was performed in TAE buffer on 100-150 mV. Detection of DNA 
fragments was done in ethidium-bromide containing water. 
3.1.5.3.2 Subcloning and sequencing 
In order to identify mutations, we used pGEM-T Easy Vector System for 
subcloning PCR products. This vector contains a T7 and an SP6 sequence, as well as a -
galactosidase coding sequence and a standard ampicillin selection cassette to screen for 
recombinant clones. Purified PCR products were ligated to linearized pGEM-T vector 
containing a 3’-terminal thymidine at both ends by T4 DNA ligase enzyme overnight at 
4ºC. DNA insert was used at 1:3 ratio of vector to insert, respectively. Transformation 
was done in DH10B E. Coli bacteria strain by adding the ligation mix and performing 
heat shock at 42ºC for 90 seconds. This was followed by a 2-minute incubation on ice. 
Then, 300 l of LB medium was added to the tube and bacteria was incubated for 1.5-2 
hours at 37 ºC, shaking at 120 rpm. Then, 100 l of transformation culture was plated on 
agar plates with Ampicillin resistance and IPTG/X-Gal.  Recombinant colonies (white) 
were picked and plasmids were purified by Qiagen Mini Kit. Products were sequenced 
by T7 or SP6 primers at the CNIO Genomics Unit.  Sequences were aligned and analyzed 
utilizing MultAlin program. 
3.1.6 Subcutaneous and orthotopic allograft models 
Immunodeficient NU-Foxn1nu mice (females, 5-weeks-old) were purchased from 
Harlan Laboratories. Tumor (0.5x106) cells only or in combination with (0.5x106) CAFs 
or NPFs were injected in PBS:Matrigel (1:1) into dorsal flanks of the mice. Growth was 
measured every 3 days until humane end point. Orthotopic injection was performed by 
surgery under anesthesia (4% Isofluorane) utilizing the same number of cells for injection 
as in the subcutaneous model. Tumor growth was monitored by micro-ultrasound (Vevo 
770, Visualsonics, Toronto, Canada). Mice were sacrificed 3-weeks-post-injection. 
Tumor volume was limited to 1,500 mm3. Tumors were measured by caliper and 
calculated as Length x Width2/2. 
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3.2 Isolation of cells – tissue culture 
3.2.1 Generation of fibroblasts and tumor cells by outgrowth 
Primary fibroblasts were isolated from fresh tissue samples collected from tumor-
bearing KPeCY or WT mice. The tissue was minced by a sterile surgical blade and cells 
were incubated in collagenase P solution (1,5 g/ml in Hank’s Balanced Salt Solution, 
HBSS) solution for 30-60 minutes at 37C. Cells were washed with 5% FBS-HBSS, 
centrifuged and plated in 6 cm Petri dish with DMEM+10% FBS and 1% 
Penicillin/Streptomycin. The following day, tissue pieces were removed and placed in a 
new Petri dish to avoid epithelial cell contamination of fibroblast cultures and tumor cells 
were allowed to growth out from tissue pieces. In the case of CAFs, differential 
trypsinization was used in order to eliminate remnant tumor cells. This method takes 
advantage of the faster attachment/detachment of fibroblasts compared to other cell types. 
Cells were washed with PBS, which was followed by trypsinizing the cells for 30 seconds 
at 37C and seeding them to a separate culture plate. The second washing and 
trypsinization step (5 mins, 37C) contained the tumor cells in higher proportion. Culture 
media was changed every 3 days. 
3.2.2 Isolation by cell sorting 
CAFs and tumor cells were obtained by mechanical dissociation of freshly 
dissected tumor tissue and digested in Collagenase solution (0,5 mg/ml Collagenase P – 
HBSS with 0,2 %BSA) for 30 min, at 37ºC shaking in a 250-ml flask. Then cells were 
washed and centrifuged in ice cold 5% FBS-HBSS washing buffer containing 0,01% 
DNase. After two steps of filtration (100 m and 40 m cell strainer), erythrocytes were 
lysed by 30s incubation with ACK lysis buffer (Lonza), and cells were resuspended in 
PBS containing 0.5% BSA and 2 mM EDTA. Before analysis, single cell suspensions 
were preincubated with purified anti-mouse CD16/32 antibodies (1:200; BD Pharmingen) 
for 15 min on ice to block nonspecific Fc receptor-mediated binding. Aliquots of 0,5×106 
cells were stained for 30-45 min at room temperature with the following antibodies: APC 
anti-mouse CD31 (1:200, clone MEC 13.3, BD Biosciences), APC anti-mouse CD45 
(1:200, clone 30-F11, BD Biosciences), FITC anti-mouse CD326 (EpCAM, 1:200, clone: 
G8.8, Biolegend), PE anti-mouse CD140a (PDGFR, 1:100, clone: APA5, eBioscience). 
Samples were processed to Influx cell sorter (BD Pharmingen) and separated directly into 
Trizol (RNA isolation) or PBS (cell culture). Cells were plated in 6 cm Petri dishes and 
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cultured in DMEM+10%FBS. Primary cultures were expanded and frozen at passage 2 
(P2). Çell lines were generated by serial passaging. 
3.2.3 Tumor organoid – fibroblast co-cultures 
Organoids were established from tumor tissues obtained from KPeCY mice at 
humane end point based on previously described protocol (216). Fibroblasts were plated 
(1x105) in 24 well glass bottom plates (Greiner Bio-One). Organoids were passed at 1:6 
dilution from confluent 24 well plates. Organoids were co-cultured with fibroblast in 
basic media without factors (Advanced DMEM + Hepes + Glutamax) for 5 days. Images 
were acquired in a Leica DMI6000B wide field microscope (Leica Microsystems) 
equipped with a 5X NA, 0.15 dry objective and an incubator chamber at 37ºC and 5% of 
CO2. Leica AF and Leica HCS-A software were used for the acquisition.  
3.2.4 Wound healing and migration assay 
To perform wound healing and migration assays 0,5x106 cells were plated into 6-
well cell culture plate. Cells were allowed to grow in 10% FBS containing DMEM 
medium to confluence into 6-well plates. Three vertical 1- mm wide scratches were made 
across the cell layer using a sterile pipette tip. After washing with PBS, serum free DMEM  
medium was added (217). Wound healing assays were acquired in a Leica DMI6000B 
wide field microscope (Leica Microsystems). Images were acquired with bright-field 
method every 10 minutes during 20 hours and were processed by Fiji software. 
3.2.5 Lentiviral infection of cells 
Lentiviral supernatants were prepared through transfection of HEK293T cells at 
70%-80% confluence. Packaging plasmids pLP1 (1.95μg), pLP2 (1.3μg), pLP/VSVG 
(1.64μg) (Invitrogen) and the lentiviral shRNA sequence (5μg) were mixed and added to 
40μl of Polyethylenimine (1mg/ml) and 500μl serum free DMEM. The mixture was 
vortexed for 5 seconds and incubated at RT for 15 minutes. HEK293T cells were 
transfected dropwise. Transfected cells were incubated at 37C overnight. The following 
day, cells were placed at 32°C for 24-48 hours. Lentiviral supernatant was collected and 
filtered (0.45μm) into DMEM containing Polybrene (8μg/ml). Cells were infected at 50 
% confluency. After infection cells were grown for 24 hours at 32°C followed by a growth 
period for additional 24 hours at 37C. Subsequently, cells were selected with 2μg/ml 
puromycin for 1 week. For Saa3 (TRCN0000100095, TRCN0000100248), Lum 
DOI:10.14753/SE.2018.2172
  
 
46 
(TRCN0000094640), Has1 (TRCN0000028846) and Mpp6 (TRCN0000361747) 
knockdown assays, cells were infected using lentiviral particles generated with Mission-
shRNA plasmids (Sigma). Non-Target shRNA control vector (sh-Ctrl) was used as a 
negative control.  
3.3 Gene expression profiling 
3.3.1 RNA extraction from sorted cells 
Total RNA was extracted from 5000-20000 cells directly sorted into 1 ml Trizol 
and the tubes were directly frozen on dry ice to avoid degradation of RNA. After thawing, 
samples were vortexed for 15 seconds and 200 l of chloroform was added. To separate 
phases, samples were mixed thoroughly and let for 2 mins at RT followed by 10 mins of 
centrifugation at 4ºC, 12000 rpm. Next, aqueous phase was transferred carefully into a 
new tube and 1 volume of 70% ethanol was added. This tube already contained 1 l of 
Glycogen and 3 l of Linear Polyacrylamide (LPA) in order to enhance precipitation of 
the small amount of RNA. Samples were mixed and centrifuged at 13200 rpm at RT. 
Supernatant was aspirated using vacuum and samples were air-dried for 30-60 mins at 
RT. RNA clean-up was performed when necessary by Qiagen (see 3.10.1). RNA quality 
was measured by Bioanalyzer. 
3.3.2 RNA sequencing, gene expression profiling and GSEA analysis 
Poly-A pull-down was utilized to enrich mRNAs from total RNA samples (200 ng-
1 g per sample, RIN>8 required) and proceeded to library preparation by using Illumina 
TruSeq RNA prep kit. Libraries were then sequenced using Illumina HiSeq2000 at 
Columbia Genome Center. Samples were multiplexed in each lane, which yields 
targeted number of single-end/paired-end 100bp reads for each sample, as a fraction of 
180 million reads for the whole lane. RTA (Illumina) was used for base calling and 
bcl2fastq (version 1.8.4) for converting BCL to fastq format, coupled with adaptor 
trimming. Reads were analyzed with the Nextpresso pipeline (218). Sequencing quality 
was checked with FastQC v0.11.0. Reads were aligned to the human genome 
(GRCh37/hg19) with TopHat-2.0.10 using Bowtie 1.0.0 (219) and Samtools 0.1.1.9 
(220), allowing two mismatches and 20 multihits. Gene Set Enrichment Analysis was 
performed with GSEAPreranked (221), setting 1000 gene set permutations. Only those 
gene sets, with significant enrichment levels (FDR q-value < 0.25) were considered.  
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3.4 Imaging  
3.4.1 Tumor monitoring by micro-ultrasound  
Mice were anesthetized with 4% isoflurane (Braun Vetcare) in 100% oxygen at a 
rate of 1.5 liter/min. Hypothermia associated with anesthesia was avoided using a bed-
heater. Abdominal hair was removed by depilation cream to prepare the examination area. 
Mice were screened for PDAC and tumors were measured with a micro-ultrasound 
system Vevo 770 (Visualsonics, Toronto, Canada) with an ultrasound transducer of 40 
MHz (RMV704, Visualsonics, Toronto, Canada). PDAC size was calculated as Length x 
Width2/2.  
3.4.2 Imaging by contrast agent  
Tumor perfusion and vascularization study was performed by administration of 
MicroMarker Contrast agent (VisualSonics). Gas filled bubbles surrounded by 
phospholipid monolayer were injected intraveniously directly before ultrasound 
measurements. Efficiency of contrast agent perfusion was measured within the tumor. 
3.5 Treatments 
Mice were treated twice a week with Gemcitabine (Gemzar) (100 mg/kg) or Saline 
IP, 100µl volume. Combination treatment of Gemcitabine and anti-VEGF monoclonal 
antibody B20 4.1.1 (5 mg/kg, Genentech) or macrophage depleting agent Clodronate (50 
mg/kg, Clodronate Liposomes) were administered at the same time IP. Tumor growth 
was followed weekly by microultrasound. Mice were treated until humane end point to 
study survival. 
3.6 Processing of mouse tissues 
3.6.1 Necropsies 
Necropsies were performed in the CNIO Pathology laboratory. Mice were 
euthanized in a CO2 chamber, tissue samples were collected either in 10% buffered 
formalin, embedded in OCT and/or frozen to be sectioned at a later time on a microtome-
cryostat or directly frozen in dry ice for extraction of protein, DNA or RNA. The 
Comparative Pathology Unit of CNIO processed all the formalin-fixed tissues samples.  
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3.6.2 Histology – Immunohistochemistry 
For histological analyses, tissues were fixed in 10% buffered formalin and 
embedded in paraffin. Hematoxylin & Eosin (H&E) staining and IHC analyses were 
performed on 3 μm paraffin sections. For IHC, the following antibodies were used: anti-
mouse CD31 (1:50, Abcam), anti-mouse F4/80 (1:20, ABD Serotec, CI: A3-1), anti-
mouse CK19 (TROMA III, CNIO Monoclonal Antibody Unit), anti-mouse Ki67 (SP6, 
Master Diagnostica), GFP Mouse Monoclonal (1:500, Roche), anti-mouse Cleaved 
Caspase 3 (Asp 175) (1:750 Cell signaling, 9661), anti-mouse Phospho-Histone H3 
(Ser10) (1:500, Millipore), anti-mouse CD3 (1:250, Santa Cruz Biotechnology, M20), 
anti-mouse MPO (1:1250, Dako, A0398), anti-mouse Pax5 (1:500, Santa Cruz 
Biotechnology, C-20). Digital images of immunostained slides were obtained at 40X 
magnification (0.12 μm/pixel) using a whole slide scanner (Mirax scan, Zeiss) fitted with 
a 40X/0.95 Plan Apochromat objective lens (Zeiss). Images were analyzed by ZEN2 
software. At least 4 tumors were sectioned and one section was analyzed for 
quantification of each staining.  
3.6.3 Immunofluorescence 
CAFs and NPFs (5x105 cells/well) were plated in 24-well plates using BioCoat 
Poly-D-Lysin (Cellware) coverslips and allowed to grow for 24h. Tissue samples were 
sectioned (10m) by Cryostat from OCT blocks. Samples were fixed in 4% 
paraformaldehyde (Electron Microscopy Sciences). Permeabilization was performed by 
0.2% Triton X-100 solution. Primary antibodies including those elicited against SMA 
(1:100, Biocare Medical), anti-mouse PDGFRα (CD140a, 1:100, clone: APA5, 
eBioscience) were incubated overnight at 40C followed by the addition of secondary 
antibody, Alexa Fluor 594 at 1:200 for 1h at room temperature, then Hoescht (Invitrogen) 
staining was applied. Sections were mounted with Mowiol. Captures were performed 
with a TCS SP5 confocal microscope (Leica Microsystems) equipped with a 20X NA, 
0.7 dry, a 20X 0.7 multi-immersion and a 40X NA, 1.25 oil objectives. Leica AF software 
was used for acquiring and processing the images. 
3.7 FACS analysis 
Single cell preparation was performed as described above, otherwise cell were 
trypsinized and resuspended in PBS. Before analysis, cells were preincubated with 
purified anti-mouse CD16/32 antibodies (1:200; BD Pharmingen) for 15 min on ice to 
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block nonspecific Fc receptor-mediated binding. Cells were immunostained with APC-
Cy7 anti-mouse SMA (1:75, Abcore), PE anti-mouse CD140a (PDGFRα, 1:100, clone: 
APA5, eBioscience). For cancer stem cell (CSC), population PE anti-mouse CXCR4 
(1:100, clone: 2B11, BD Biosciences), APC anti-mouse CD133 (1:100, clone:13A4, 
eBioscience) PE-Cy7 anti-mouse CD44 (1:100, clone: IM7), FITC anti-mouse CD326 
(EpCAM, 1:200, clone: G8.8 Biolegend) were used. Monocyte/macrophage profiling: 
anti-mouse F4/80 (1:100, clone: BM8, eBioscience), anti-mouse PE-Cy7 CD11b (1:100, 
clone: M1-70, BD Biosciences), PerCP-Cy5.5 anti-mouse CD11c (1:100, clone: N418, 
eBioscience), anti-mouse CD206 PE (1:50, Serotec). Samples were processed on a FACS 
CANTO II flow cytometer (BD Pharmingen) and analyzed using FlowJo (Tree Star).  
3.8 Western blot 
3.8.1 Protein extraction 
Cells were washed and collected in NP40 lysis buffer: 50mM Tris-HCl pH 7.4, 
150mM NaCl, 0.5% NP40, and a freshly added cocktail of protease and phosphatase 
inhibitors (cOmplete Mini, Roche; Phosphatase Inhibitor Cocktail 2 and 3, Sigma-
Aldrich). Samples were incubated on ice for 30 minutes and were centrifuged for 20 
minutes at 13,000 rpm and 4ºC. Supernatant was transferred to a new tube and protein 
concentration was measured by Bradford reagent (Bio-Rad). Standard curve was prepared 
from 1mg/ml Bovine Serum Albumin (BSA). 2μl of the protein extract was added to 1ml 
of 1:4 Bradford reagent and the absorbance was read at 595nm by spectrophotometer. 
Standard curve was prepared from 1mg/ml Bovine Serum Albumin (BSA).  
3.8.2 Blotting 
Cell lysates (50μg) were mixed with 4X loading buffer and 10X reducing agent 
(Thermo Fisher Scientific). To denature protein, samples were boiled for 4 minutes at 
95ºC. After spin down, they were loaded on 4-12% Nupage Bis-Tris gels (Thermo Fisher 
Scientific) and separated in MES 1X buffer (Thermo Fisher Scientific). 8μl of Spectra 
Multicolor Broad Range Protein Ladder (Thermo Fisher Scientific) was used for 
molecular weight reference. Nitrocellulose transfer membrane (GE Healthcare) and 
Whatman 3MM (Sigma- Aldrich) paper were sized to gel and prewet in transfer buffer 
(Tris-Glycine 1X, Lonza; Methanol 20%). A “transfer sandwich” was assembled in the 
following order: cathode, sponge, 3x Whatman paper, gel, nitrocellulose membrane 3x 
Whatman paper, sponge, anode. The gel was transferred for 60 minutes at a constant 
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current of 400 mA and maximum power on ice or at 4ºC. Afterwards, staining with 
Ponceau S solution (Sigma) was performed to check the efficiency of protein transfer. 
Membranes were blocked by incubation with 5% non-fat milk in TBST (1X Tris-Buffered 
Saline (TBS) solution; 0.1% of Tween-20) for 45 minutes at RT, shaking. Incubation with 
primary antibodies diluted in milk was performed overnight, 4ºC. The next day, the 
membranes were washed three times with 1X TBST buffer for 15 minutes on a shaking 
platform at RT. Next, blots were incubated for 1h with HRP (1:2000, Dako) labelled 
secondary antibodies. Protein visualization was done with chemiluminiscent system 
(ECL; Amersham, GE Healthcare). Membranes were blotted with antibodies against 
Lumican (1:2000, rabbit monoclonal, EPR8898, Abcam), and Gapdh (1:10000; Mouse 
monoclonal; Sigma-Aldrich G8795) for loading control.  
3.9 Genotyping  
Most of the genetic modifications were genotyped by Transnetyx (Cordoba, TN, 
USA). For Saa3 alleles, PCR reaction was done as following. Genomic DNA was isolated 
from mouse tails, genotyping was performed by PCR. Each reaction contained: 1μl 
MgCl2 (25mM), 2μl Taq-Polymerase Buffer 1X, 0.25μl dNTPs 10mM, 0.2μl BSA 10 
mg/ml, 0.2μl Taq-Polymerase (5U/μl EcoTaq, Ecogen), 0.5μl of each of the primers 
(10μM, Sigma), 1μl of DNA filled up to 20μl of sterile water. The following primers were 
used for genotyping the Saa3 alleles: 
Forward WT: 5-AAGCTCTCTCTGAAATGGTCCAG-3 
Reverse WT: 5-TTTCTCCCATTGCTTTGTGCTAGGC-3 
Reverse KO: 5-GTGGGAAGTGATTTTGCCATCAGCC-3 
3.9.1 DNA extraction 
At weaning, mouse tail was cut to extract genomic DNA. Cells were cultured, 
harvested and collected in pellets. Tissues and cells were incubated with a lysis buffer 
(20mM Tris-HCl pH 8.0, 100mM NaCl, 0.5% SDS, 10mM EDTA pH 8.0 and MilliQ 
H2O) and 400μg/ml of proteinase K overnight at 55ºC. The next day, 300μl of saturated 
NaCl were added to the digested sample. After mixing vigorously by inversion, the mix 
was incubated on ice for 10 minutes. The samples were then centrifuged at 13,200 rpm 
for 10 minutes at 4ºC. The supernatant was transferred into a clean tube, and DNA was 
precipitated by adding 800μl of isopropanol. After mixing and incubating the solution for 
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at least 5 minutes at RT, the samples were centrifuged at 13,200 rpm for 30 minutes at 
4ºC. The supernatant was discarded and the pellets were washed with 500μl of 70% 
ethanol. The samples were centrifuged again at 13,200 rpm for 5 minutes at 4ºC. Finally, 
the pellets were left to air dry. Dry pellets were resuspended in 100μl of sterile water. 
3.9.2 General PCR reaction 
Genomic DNA from mouse tails was used for genotyping by Polymerase Chain 
Reaction (PCR). Each reaction contained: 1μl MgCl2 25mM, 2μl Taq-Polymerase Buffer 
1X, 0.25μl dNTPs 10mM, 0.2μl BSA 10 mg/ml, 0.1μl Taq-Polymerase (5U/μl EcoTaq, 
Ecogen), 0.75μl of each of the primers (10μM, Sigma), 1μl of DNA and up to 20μl of 
MilliQ H2O. General PCR program used: denaturation at 94°C for 1 minute, followed by 
35 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and 
extension at 72°C for 30s, and a long extension at 72°C for 10 minutes as final step.  
3.10 Quantitative Real Time – PCR (qRT-PCR)  
3.10.1 RNA isolation 
Total RNA was extracted from cultured cells or from frozen tissue by Qiagen 
RNeasy Mini Kit. Briefly, cells were washed with PBS and were collected with cell 
scraper in 600 ml of RLT buffer. Tissues were mechanically disrupted using zirconium 
beads in capped tubes and were centrifuged at 2000 rpm. This lysate was loaded on 
QiaShredder columns to eliminate cell aggregate remnants. Next, 1 volume of 70% 
ethanol in RNase free water was added, the lysate was mixed and loaded to RNeasy spin 
columns. Columns were centrifuged at 10,000 rpm for 30 seconds. The RNA bound to 
the membrane of the column was washed by 700 µl RW1 buffer and on-column DNA 
digestion was performed by RNase free DNase Set (Qiagen) for 15 mins. 
3.10.2 cDNA synthesis and q – RT – PCR reaction 
cDNA synthesis was performed by reverse-transcription of 1 g RNA using Super 
Script II Reverse Transcriptase (Invitrogen) and random primers (Invitrogen) following 
the manufacturer’s instructions. 20 l cDNA reaction was diluted 1:5 in RNase free water 
and was ready to use. qRT-PCR assays were performed with a FAST7500 Real-Time 
PCR System using Power SYBR Green PCR Master Mix (Applied Biosystems) with the 
primers indicated below. Reaction was set up for 10 l containing: 5 l of SYBR Green 
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master mix; 0.25 l of forward and reverse primers (10 M); 2.7 l RNase free water; 
and 1.8 l cDNA. Triplicates were loaded for each reaction on 96 well plate. Data analysis 
was performed using ∆∆CT method (ΔΔCt = ΔCt sample – ΔCt reference). GAPDH was 
used for normalization. 
Primers for Saa1 amplification: 
5-AGGAGACACCAGGATGAAGC-3 (forward)  
5-GGAAAGCCTCGTGAACAAAT-3 (reverse) 
Primers for Saa2 amplification: 
5-CCACAAGCCTCTCTCTGTGA-3 (forward)  
5-AGTTCCCTGTTTCCATCGAC-3 (reverse) 
Primers for Saa3 amplification: 
5-TGCCATCATTCTTTGCATCT-3 (forward)  
5-AGTAGGCTCGCCACATGTCT-3 (reverse) 
Primers for CD68 amplification: 
5-AGCCATTCAAGACAAAGCCT-3 (forward)  
5-CAAGGTGAACAGCTGGAGAA-3 (reverse) 
Primers for CK19 amplification: 
5-TGTCGACCTAGCCAAGATCC-3 (forward)  
5-AAGGTAGGTGGCTTCAGCAT-3 (reverse) 
Primers for Vimentin amplification: 
5-CGGCTGCGAGAGAAATTGC-3 (forward)  
5-CCACTTTCCGTTCAAGGTCAAG-3 (reverse) 
Primers for FAP amplification: 
5-TTTCCAGGCGATGTGGTACT-3 (forward)  
5-ATGGTCCAAGTCGTCCATGT-3 (reverse) 
Primers for PDGFRα amplification: 
5-AGCCAGAAGTAGCGAGAAGC-3 (forward)  
5-GGCAGTATTCCGTGATGATG-3 (reverse) 
Primers for Mpp6 amplification:  
5-GATCTGGTAATCGCCCGAATC-3 (forward)  
5-GGTGCCTCTCCATATTGACGTA-3 (reverse)  
Primers for GAPDH amplification:  
5-CGACTCAGATGTCCCTGGAT-3 (forward)  
5-GCCTGTCCAAGCAATGAAAT-3 (reverse) 
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3.11 Human samples 
Primary tumors were obtained from the Tumor Bank of the Hospital ‘Virgen de la 
Arrixaca’ Murcia, Spain (BIOBANC-MUR, B.0000859). Specific informed consent for 
tumor implantation in mice was obtained from all patients, and the study received the 
approval of the CNIO Ethics Committee. 
DKFZ human PDAC dataset: a different set of primary tumors were used to isolate 
cell populations by cell sorting were obtained from PDAC patients at the University 
Hospital Heidelberg, Germany in collaboration with the German Cancer Research Center 
(DKFZ). The study was approved by the ethical committee of the University of 
Heidelberg and conducted in accordance with the Helsinki Declaration; written informed 
consent was obtained from all patients. Human PDAC-CAFs and normal fibroblasts were 
obtained from fresh primary PDAC specimens and adjacent normal pancreas by cell 
sorting: immunostained with FITC anti-human CD326 (EpCAM, 1:11, Clone: AC128, 
Miltenyi Biotec); VioBlue anti-human CD45 (1:11, Clone: 5B1, Miltenyi Biotec); APC 
anti-human CD31 (1:11, Clone: HEA-125, Miltenyi Biotec). Fibroblasts were defined as 
EpCAM-/CD45-/CD31- population. 
3.12 Statistical Analysis 
Data are mean  SD except for FACS analysis where representative images were 
used. Significance between two groups was assessed by the Student's two-tailed t-test. 
Data sets consisting of more than 2 groups were analyzed by analysis of variance 
(ANOVA). The product limit method of Kaplan-Meier was used for generating the 
survival curves, which were compared by using the log-rank (Mantel-Cox) test. 
Difference of metastasis appearance between two groups was analyzed by Chi-square 
test. P values < 0.05 were considered to be statistically significant (*P < 0.05, **P<0.001 
***P < 0.001). All statistical analysis was performed using GraphPad Prism software. 
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4 Results 
4.1 Targeting CAFs in PDAC 
Pancreatic Ductal Adenocarcinoma is characterized by an abundant desmoplastic 
microenvironment that constitutes up to 90% of the total tumor volume. Around 80% of 
this stroma is composed (around 80%) of cancer-associated fibroblasts (CAFs), which 
produce massive amount of ECM components and are responsible for establishing 
physical and chemical barrier to chemotherapeutic drugs (222). Therefore, CAFs may 
represent attractive target in pancreatic cancer in combination with standard of care 
treatments. To better understand tumor stroma interactions generating the defense 
mechanism of pancreatic tumors we decided to study transcriptome profiles of CAFs and 
their role in PDAC development by using mouse models. 
4.1.1 Characterization of stromal cell populations in PDAC mouse model 
To explore the populations of CAFs present in PDAC, we used a GEM tumor model 
previously generated in our laboratory, the K-Ras+/LSLG12Vgeo;Trp53lox/lox;Elas-
tTA/tetO-Cre compound strain, in which we can selectively induce the expression of a 
resident K-RasG12V oncogene and disable the Trp53 tumor suppressor in acinar cells 
during late embryonic development (92). We added a Rosa26LSLEYFP allele in order to 
have a color marker (EYFP) to identify those cells carrying the tumor initiating mutations: 
expression of the K-RasG12V oncogene and loss of p53. These mice, designated as 
KPeCY, develop PDAC tumors with complete penetrance and a latency of 3-4 months. 
More importantly, they recapitulate the human disease including the formation of a 
massive stromal desmoplasia made up of heterogeneous CAF populations. 
Interestingly, analysis of stromal tissue with antibodies elicited against αSMA and 
PDGFRα, a marker associated with inflammation (140), revealed that whereas most 
fibroblastic stromal cells of KPeCY tumors expressed αSMA, only a fraction contained 
PDGFRα (Fig 8A). FACS analysis of fresh tumors showed at least four distinct 
populations of fibroblast cells (Fig 8B). Whereas one population only expressed αSMA 
(39% of the total), other population, representing 36% of the cells, contained both 
markers, (αSMA and PDGFRα). We also identified two additional populations 
represented by those cells that only expressed PDGFRα (9%) and those that did not 
express either marker or expressed them at very low levels (16%) (Fig 8B). 
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Figure 8. Immunofluorescence and FACS analysis of CAFs. (A) (Left) 
Immunofluorescence staining with anti-SMA (green) and anti-PDGFR (red) 
antibodies and with EYFP (yellow) of a KPeCY PDAC tumor. (Right) Higher 
magnification of PDGFR (red) and EYFP (yellow) positive cells. Scale bars, 100 m. 
(B) (Left) FACS analysis of fresh tumor samples with CD31/CD45 and EYFP markers. 
(Right) FACS analysis of CD31/CD45/EYFP negative cells with anti-SMA and anti-
PDGFR antibodies. The percentages of SMA and PDGFR single positive cells as 
well as SMA/PDGFR double negative and double positive cells are indicated. 
4.1.2 Isolation of CAFs from PDAC and NPFs from normal pancreas  
Several methods were used previously to isolate fibroblasts from different tumor 
types and from normal tissues (155, 157, 223). In order to establish an efficient way to 
separate fibroblasts and to compare distinct populations we isolated stromal cells by two 
methods. 
4.1.2.1 Fibroblast isolation by “outgrowth” 
First, we isolated CAFs and normal pancreatic fibroblasts (NPFs) by “outgrowth 
method” [(155), section 1.3.1], where all types of cells are allowed to grow out from 
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tissue pieces and attach to the culture plate. However, separation of a mixed cell 
population needs to be addressed afterwards. We used differential trypsinization to obtain 
pure fibroblast population. This method takes advantage of the faster detachment of 
fibroblasts compared to epithelial cells upon trypsinization. Purity was verified by the 
expression of fibroblast-specific genes (Vimentin, PDGFRα and αSMA) qPCR and 
immunofluorescence and the lack of tumor and immune cell markers Cytokeratin 19 
(CK19), CD45, CD68, F4/80 respectively analyzed by qPCR. 
This method is simple and fast but has important disadvantages: the culture is a 
mixture of populations and CAFs adapt to the plate, resulting in expression pattern 
alterations and can influence target identification. To bypass this issue, we selected a 
more physiological isolation method. 
4.1.2.2 Fibroblast isolation by cell sorting using PDGFR  
We isolated CAFs by FACS. For this method, it is essential to use cell surface 
specific markers. We selected a subset of fibroblasts by the cell surface marker 
PDGFRα+. We sorted PDGFRα+/EYFP-/CD45-/CD31- stromal cells from PDAC 
tumors of KPeCY mice as well as from normal pancreata of control Elas-tTA/tetO-
Cre;Rosa26+/LSLEYFP animals (Fig 9A and B). These cells represented 21% and 15% 
respectively, of the EYFP-/CD45-/CD31- population and were subjected to direct RNA 
isolation with the aim of performing RNAseq analysis. We also established primary cells 
in culture and cell lines for in vitro studies. These cultured cells retained αSMA and 
PDGFRα expression and displayed the spindle shape characteristic of fibroblasts, at least 
until 30 passages (Fig 9C, D). The fibroblastic nature of these cells was further verified 
by the expression of fibroblast-specific genes including FAP, Vimentin, PDGFR, as 
well as by the lack of immune (CD45, CD68) and tumor (CK19, EpCAM) cell markers 
(Fig 9B and E). These results show that this cell population does not contain tumor or 
immune cells. In addition, we considered these fibroblasts sorted from tumors as CAFs 
and cells sorted from normal pancreas as NPFs. Altogether, these results indicate that the 
PDGFRα+ stromal cells isolated from KPeCY tumors represent CAFs whereas those 
obtained from normal pancreata represent NPFs. The latter had slightly higher levels of 
αSMA than CAFs, a property that has been proposed to represent a marker of myo-
fibroblast activation (Fig 9D) (127).  
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Figure 9. FACS isolation and verification of PDGFRα+ CAFs and NPFs. (A) 
Schematic diagram of the strategy followed in this study to sort the different cell 
populations from GEM PDAC tumors. Immune cells were separated by CD45 expression, 
endothelial cells by CD31 staining, tumor cells by the EYFP marker and EPCAM-FITC 
staining and CAFs by PDGFRα expression. Cells were used for cell culture, RNAseq and 
in vivo tumor growth studies. (B) Cell sorting of KPeCY PDAC tumors and normal 
pancreata from control mice selected with DAPI, anti-CD31 and CD45, anti-EPCAM, 
and anti–PDGFRα and EYFP. The percentages of NPFs and CAFs are indicated. (C) 
Immunofluorescence staining of sorted CAFs and NPFs after expansion in culture with 
anti-SMA (green) and anti-PDGFRα (red) antibodies. Scale bars, 50 m. (D) (Upper) 
A representative FACS analysis of αSMA/PDGFR co-expression in CAF and NPF 
cells. (Lower) FACS histogram representing the αSMA expression intensity in CAFs 
(red) and NPFs (blue). (E) Expression levels of CD68 (immune cell marker), CK19 
(tumor cell marker); and Vimentin (Vim), FAP and PDGFRα (fibroblast markers) 
analyzed by qPCR (relative to GAPDH expression) in tumor cells (red bars), NPFs (open 
bars) and CAFs (solid bars). 
4.1.2.3 Tumor promoting PDGFRα+ CAFs and tumor suppressing PDGFRα+ 
NPFs 
It was described by several groups that CAFs display pro- and anti-tumorigenic 
properties (130, 173). To determine whether PDGFRα+ CAFs can promote 
tumorigenesis, we compared their tumor supporting capabilities with those of NPFs using 
in vivo assays. EYFP+ sorted PDAC tumor cells (0.5x106) isolated from tumor-bearing 
KPeCY mice were subcutaneously inoculated alone or in combination with CAFs 
(0.5x106) or NPFs (0.5x106) into the flanks of immunocompromised mice. Whereas 
CAFs stimulated tumor growth by as much as 75%, NPFs inhibited the proliferation of 
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the pancreatic tumor cells by as much as 65% (Fig 10). These results illustrate the pro-
tumorigenic activity of the PDGFRα+ subpopulation of CAFs used in this study.  
 
Figure 10. Pro- and anti-tumorigenic fibroblasts in a subcutaneous mouse model. 
Growth of PDAC tumor cells (0.5 x 106) injected subcutaneously in 
immunocompromised mice either alone (red circles) or co-injected with the same amount 
of CAFs (solid circles) or NPFs (open circles) (*P < 0.05, **P<0.001). 
4.1.2.4 Comparative transcriptional profiling of CAFs versus NPFs 
Understanding the biology and the molecular pattern changes of heterogeneous 
CAF populations is increasingly important in order to develop efficient therapies 
targeting the stroma in PDAC. In this thesis work, we compared transcriptome profiles 
of distinct CAF populations isolated by two different methods. 
4.1.2.4.1 Gene expression profiling of fibroblasts from “outgrowth” 
To better characterize the cells isolated by outgrowth from normal (WT) pancreas 
and PDACs we performed RNA sequencing (RNAseq) of NPFs (n = 3) and CAFs (n = 
3). It is important to take into consideration that these cells were cultured in vitro at least 
for 2 weeks, time that could presumably alter their gene expression profiles compared to 
freshly isolated cells.  
To broaden our understanding of general CAF characteristics, first, we performed 
a pathway analysis comparing CAF to NPF expression patterns. Gene Set Enrichment 
Analysis (GSEA) revealed significantly increased activity in the Complement Cascade, 
Toll-like receptor and NFB signaling, as well as upregulation of Cytokine-Receptor 
Interaction (Fig 11A) suggesting highly elevated innate immune response. On the other 
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hand, we observed downregulation of genes from Cell cycle and Vascular smooth muscle 
contraction gene sets in CAFs compared to NPFs (Fig 11A).  
Differential expression study demonstrated a high number of differentially 
regulated genes (n = 730). Among the top upregulated genes (Fig 11B), there were Serum 
Amyloid A3 (Saa3, log2 fold change = 7,42), Haptoglobin (Hp, log2 fold change = 6,51) 
and Apolipoprotein B (Apob, log2 fold change = 6,50). These three genes are associated 
with ‘Acute phase response’, suggesting a key role of this complex pathway in CAF 
reprogramming. 
 
 
Figure 11. Transcriptional profiling of CAFs by “outgrowth”. (A) GSEA pathway 
analysis of CAFs compared to NPFs isolated by outgrowth. (B) Top 25 upregulated genes 
identified in CAFs compared to NPFs. 
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4.1.2.4.2 Gene expression profiling of PDGFRα+ CAFs and NPFs isolated by cell 
sorting 
To understand the molecular bases responsible for the tumor-promoting activity of 
PDGFRα+ CAFs compared to the PDGFRα+ NPFs, we performed a comparative study 
of the transcriptome profiles of freshly isolated CAFs (n = 5) with those of NPFs (n = 3) 
by RNA sequencing analysis. As illustrated in Figure 12A, CAFs displayed a strong 
inflammatory profile, in which many of the top upregulated genes included those 
encoding cytokines, such as Il1ß and Il6, chemokines like Cxcl1 and Ccl22, as well as 
other interleukins and TNF family members related to the innate immune response. 
Furthermore, Gene Set Enrichment Analysis (GSEA) confirmed the upregulation of the 
immune cell recruiting Complement Cascade, IL-1R signaling, and JAK-STAT pathways 
in CAFs. This analysis also identified the Cytokine/Receptor signaling as one of the most 
significantly upregulated pathways in CAFs compared to NPFs (Fig 12B and C). In 
addition, we observed a high enrichment in cell-to-cell junction pathways suggesting the 
presence of active contact-mediated signaling in CAFs (Fig 12B and C), a property that 
may have an important role in tumor promotion (224). CAFs also displayed upregulation 
of TGF-ß and Hedgehog signaling pathways as well as ECM/Receptor interactions (Fig 
12C), a set of transcriptional changes thought to result from their crosstalk with the tumor 
cells (151, 170). 
Downregulated hallmarks included Oxidative Phosphorylation suggesting that 
CAFs have undergone a metabolic reprogramming and oxidative stress (Fig 12C). The 
latter was further supported by significant downregulation of genes involved in Peptide 
Elongation, Translation and Protein Metabolism, hallmarks of stress responses indicating 
mitochondrial dysfunction. We also observed a significant reduction of P53 signaling-
related genes, suggesting cell death evasion (148, 225). These results, taken together, 
support the concept that the CAFs used in this study possess a unique secretory-
inflammatory gene signature with emphasis in the activation of the innate immune 
response (Fig 12) as well as impaired oxidative phosphorylation (Fig 12C). 
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Figure 12. Transcriptional profiling of PDGFRα+ CAFs. (A) Heat map representing 
color-coded expression levels of differentially expressed inflammatory genes in CAFs (n 
= 5) versus NPFs (n = 3). (B) GSEA gene set enrichment analysis of CAFs: significantly 
upregulated inflammatory and cell adhesion pathways (FDR: False Discovery Rate). (C) 
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GSEA pathway analysis illustrating 10 significantly up- and downregulated pathways 
in CAFs. The Normalized Enrichment Score (NES) ranking was generated by the GSEA.  
4.1.2.4.3 Target selection and validation 
Comparison of gene expression profiling data of fibroblasts isolated by either 
outgrowth or by cell sorting led us to a list of differentially regulated genes. The 
difference in expression patterns is mainly due to the CAF isolation method and to the 
nature of the isolated populations (pool of CAFs vs. PDGFRα+ population). We found 
488 genes significantly upregulated in CAFs compared to NPFs isolated by the outgrowth 
method and 297 genes upregulated in PDGFRα+ CAFs isolated by FACS. Only 117 
genes were found in both groups, including Saa3 as the top overexpressed gene (Fig 13A). 
On the other hand, downregulated genes were present in a lower number, however in 
PDGFRα+ population up- and downregulated genes were distributed more evenly 
compared to the one isolated by outgrowth (Fig 13B). PDGFRα+ CAFs displayed 165 
genes downregulated, whilst the other group had only 80, where 27 was shared (Fig 13B). 
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Figure 13. Differentially regulated gene comparison in distinct CAF populations. (A) 
Venn diagram of upregulated genes shared by CAFs compared to NPFs isolated by 
distinct methods: outgrowth or sorted by PDGFRα. (B) Venn diagram of downregulated 
genes in common between the two CAF populations. 
Pharmacologically, targeting overexpressed proteins by inhibiting their function is more 
feasible than to increase the activity of downregulated genes. Therefore, to select 
potentially “druggable” targets we considered the upregulated genes. We identified 117 
commonly overexpressed genes in both CAF populations and submitted for Gene 
Ontology analysis (GO). Interestingly, the majority of the encoded proteins are secreted 
proteins (n = 48) and membrane-associated proteins (n = 27) (Fig 14A). To further 
characterize these genes, we annotated them to GO terms by molecular function, where 
more than 50% presented cytokine, chemokine or growth factor activity followed by 
groups enriched in receptor or protein binding (Fig 14B).
 
DOI:10.14753/SE.2018.2172
65 
 
Figure 14. Molecular function of target candidates. (A) Gene Ontology study of the 
117 commonly overexpressed genes in CAFs grouped by cellular component. (B) Gene 
annotations at molecular level by functions. 
4.1.2.4.4 Validation of RNAseq results by quantitative RT-PCR 
Next, we selected potential targets from the list of 117 commonly overexpressed 
genes for validation at RNA level by quantitative RT-PCR. Gene expression was 
validated in PDGFRα+ NPFs, PDGFRα+ CAFs and tumor cell samples isolated by cell 
sorting. Only secreted, extracellular or membrane proteins were considered with a 
putative role in CAF – tumor cell cross talk.  
 
Figure 15. Target validation and selection. (A) qRT-PCR validation of RNA seq gene 
expression results in PDGFRα+ NPFs (green) and CAFs (grey), as well as tumor cells. 
(B) Table of selected candidate genes. Expression values are divided in No/Low/High in 
the case of NPFs and into High/Low in CAFs. 
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Taken all together after verifying the expression by qRT-PCR we defined the following 
criteria for target selection and further validation: 
• Secreted or membrane protein – ‘druggability’. 
• Significant overexpression in CAFs compared to NPFs. 
• No or low expression in NPFs on order to avoid toxicity upon therapeutic 
inhibition. 
• Functional relevance in tumor development. 
• Strategic tools for functional studies (available antibodies). 
• Information of viability of germline knock-out mouse models. 
• Relevance to human disease: expression in human PDAC. 
Among the overexpressed targets, Saa3 presented the highest expression in CAFs 
with almost no expression in NPFs suggesting no harmful effect on normal homeostasis 
upon inhibition. In addition, based on the above criteria and on literature evidence of 
functional relevance Lumican (Lum), Haptoglobin (Hp) and Hyaluronic acid synthase 1 
(Has1), as well as Mesothelin (Msln) were selected for further functional validation and 
in vivo characterization. Saa3 and Haptoglobin are acute phase proteins and are associated 
with chronic inflammation (175, 226). Lumican and Has1 have an important role in ECM 
remodeling. Lumican overexpression in tumor cells was associated with better prognosis, 
however stromal expression was correlated with significantly worse survival, 
invasiveness and metastasis (227). Has1 is responsible for hyaluronic acid production, 
the matrix component that defines structure and physical properties of the stroma, as well 
as for regulation of inflammatory processes (163, 228). Mesothelin is a tumor 
differentiation antigen and is proposed as a reliable marker of pancreatic cancer (22), yet 
its function has not been addressed properly. 
From this point onwards, all experiments were performed only in fibroblasts 
isolated by cell sorting, selected by PDGFRα and will be referred as CAFs and NPFs. 
4.1.3 In vivo functional validation – mouse models 
4.1.3.1 Subcutaneous allograft models  
To functionally validate the selected targets, we decided to use an in vivo system 
by injecting tumor cells alongside with CAFs subcutaneously into the flanks of nude mice 
and monitor tumor growth as previously shown (Fig 10). In order to address the effect of 
the target genes in CAFs on tumor growth we used RNA interference to knock-down the 
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selected gene’s activity. CAFs were infected with ‘shTarget’ or ‘shControl’ containing 
virus, knock-down efficiency was measured by qRT-PCR (Fig 16A and B). However, 
since we couldn’t obtain a 100% downregulation, the most efficient sequence was used 
to perform co-injection experiments.  
As depicted on Figure 16, tumor cells (0.5x106) inoculated with CAFs treated with 
non-target shRNA control (0,5x106) favored tumor growth and increased tumor size by 
75% compared to tumor cells alone. While knock-down of Has1 in CAFs resulted in 
reduced tumor growth compared to CAFs treated with control shRNA, however these 
differences were not significant (Fig 16C). Similarly, downregulation of Lum decreased 
tumor size in a non-significant manner. Finally, Saa3 knock-down caused the highest 
reduction of tumor cell growth (Fig 16C). These results indicate that each of these three 
genes (Lum, Has1 and Saa3) have a functional role in PDAC promotion and suggest that 
a significant reduction in tumor size could be obtained by achieving a complete 
elimination of any of these targets. 
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Figure 16. In vivo target validation by shRNA mediated gene silencing. (A) Scheme 
of experimental design of in vivo functional target validation. CAFs were treated with 
shRNA against the specified ‘Target’ and co-injected with tumor cells into the flanks of 
nude mice. (B) shRNA knock down efficiency for each target measured by qRT-PCR. 
(C) Tumor growth curve of tumor cells co-injected with CAFs subcutaneously into the 
flanks of nude mice. Tumor size was monitored during the experimental period (3 weeks). 
CAFs were treated with shRNA sequences against the different targets or a control 
shRNA. Combinations with tumor cells are indicated on the graph by colors: shControl 
CAFs (black) (n = 5), sh Has1 CAFs (blue) (n = 3), sh Lum CAFs (green) (n = 4), shSaa3 
CAFs (red) (n = 4), only tumor cells (grey).  
4.1.3.2 Generation of mouse models to study the role of the targets in PDAC  
Given the results obtained with the knock-down experiments in nude mice we 
decided to further validate these target genes in vivo in our PDAC mouse model. 
Therefore, we selected Saa3, Lumican, Has1 and additionally two other genes from our 
target list encoding secreted proteins: Mesothelin and Haptoglobin, both elevated in 
human PDAC development and described as potential biomarkers (229).  
Viable knockout mouse models were generated previously for all these genes (209, 
230–232) with a few phenotypic changes. Lum null mice displayed fragile skin, corneal 
opacification and disorganized dermal connective tissue with abnormal collagen fibril 
assembly (232). Has1 and Msln knockout mice are viable with no particular phenotypic 
changes (231, 233). Hp null mice had a small reduction in postnatal viability and impaired 
tissue regeneration properties (230). Saa3 knockout mice were generated and 
cryopreserved sperm was available in the KOMP repository (see section 3.3.2.). For the 
DOI:10.14753/SE.2018.2172
69 
 
other four genes, we decided to use a novel and fast approach to obtain germline KO and 
developed mouse models by CRISPR gene editing technology. (see section 3.3.4.). 
4.1.3.3 Generation of mouse models by CRISPR targeting the stroma  
4.1.3.3.1 Single guided RNA design and validation in CAF cell lines 
First, we designed guide RNA sequences targeting the first coding exons (Fig 17A) 
of each candidate gene in order to generate an early stop codon in the protein coding 
sequence upon activation of the Cas9 protein, taking advantage of the cells own DNA 
repair mechanisms, such as Non-Homologous End Joining (NHEJ). We validated the 
guide RNAs in vitro by transferring them to CAFs utilizing a dual lentiviral vector 
system. Mutations induced by the target sgRNA and the Cas9 protein were confirmed at 
DNA level by T7 endonuclease assay and Sanger sequencing. First, we performed T7 
endonuclease assay on PCR products generated in the region of the target sgRNA. This 
method uses enzymes that cleave heteroduplex DNA at mismatches and extrahelical 
loops formed by single or multiple nucleotides. Figure 17B displays the detection and 
verification of one mutation induced by Lumican sgRNA. Mutated samples were further 
analyzed by subcloning and Sanger-sequencing the DNA fragments (Fig 17B). Several 
mutational events were observed: insertions, deletions (indels) with each sgRNA. Indels, 
that induced frame shift mutation and thereby prevented the gene from translation into 
functional protein (Fig 17C), were selected for validation at protein level (Fig 17D) and 
for further experimental procedures. We repeated the same process with other genes: 
Has1, Hp and Msln. 
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Figure 17. sgRNA design and validation of Lumican. (A) Scheme of sgRNA design of 
Lumican displaying the localization of the sequences on the second exon. (B) Example 
of T7 endonuclease assay of CAFs treated with sgRNA containing lentivirus. Mutant cells 
generated heteroduplex DNA displaying double band (Mu), whereas WT cells show only 
1 band (WT). Positive control sample is depicted on the image (C+). (C) (Upper) 
Alignment of the WT Lumican sequence, the result of the sgRNA treated cells and the 
sgRNA sequence. (Lower) WT amino acid sequence of Lumican. Below the amino acid 
sequence predicted after the modification induced in sgRNA treated cells. The red arrows 
depict the STOP codons generated by the frameshift mutation occurred. (D)Western blot 
analysis of sgRNA efficiency validated in CAF cell line. sgRNA 4 and 5 reulted in 
complete elimination of Lumican protein. (E) Efficiency comparison of 5 sgRNA 
sequences targeting Lumican analyzed by western blot displayed in (D). 
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4.1.3.3.2 Direct microinjection of sgRNA into zytgotes to generate single mutant 
mice 
To confirm these results in vivo and to investigate complete ablation of the targets 
in mice, we targeted zygotes derived from our “therapeutic model”, the K-
Ras+/FSFG12V;Trp53frt/frt;Elas-tTA/tetO-FLp(o);Egfrlox/lox;c-Raflox/lox;Ub-CreERT2 strain. 
This model takes advantage of a dual recombinase system (Cre/LoxP and Flp/Frt) which 
allows temporal and spatial separation of tumor development and target elimination. 
These animals will express the Flp(o) recombinase in Elastase positive cells during late 
embryonic development leading to the expression of the resident K-RasG12V oncogene 
and to the ablation of the Trp53 tumor suppressor gene. When the tumor is developed, 
tamoxifen induced elimination of Egfr or c-Raf targets occur ubiquitously in cells 
expressing the Cre-recombinase driven by the human Ubiquitin C promoter (Blasco et al. 
unpublished). Therefore, this approach provides the possibility to mimic better the 
therapeutic response of well-established tumors. 
We microinjected Has1 targeting sgRNA along with Cas9 encoding mRNA into 
the cytoplasm of one-cell state embryos. Blastocysts derived from the injected embryos 
were transplanted into foster mothers and newborn pups were obtained (9). Efficiency of 
F0 generation mice carrying mutations was determined at weaning by the same ‘PCR – 
T7 assay’ strategy as described above. As illustrated in Figure 18, mice positive for DNA 
mismatch heteroduplexes (2, 3, 5, 7) were set up for sequencing analysis. The multiple 
mutational events occurred during embryo development were determined by Sanger 
sequencing in order to select frame shift alterations. Mice were then crossed again with 
the ‘therapeutic strain’ to generate heterozygous F1 pups. These pups were analyzed by 
PCR strategy for germ line transmission of the selected CRISPR alterations.  
In conclusion, development of single mutated Has1 KO mouse model resulted in 
44% efficiency in the F0 generation revealed by T7 assay. Future studies will address the 
role of this gene on PDAC development.  
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Figure 18. Has1 single mutated mouse strain validation. T7 endonuclease assay 
depicting 4 mice (2, 3, 5, 7) with DNA heteroduplex (multiple bands) products and 5 WT 
mice (1, 4, 6, 8, 9) with only one band. DNA ladder is marked on the right side (M). 
4.1.3.3.3 One-step generation of triple mutant mice by zygote injection  
To achieve greater therapeutic benefit and to generate faster knockout mouse 
models, we tested the efficiency of multiple stromal target deletion at once by direct 
microinjection of three different target sgRNAs. Lum, Hp and Msln guide RNAs were 
introduced along with Cas9 mRNA into the cytoplasm of zygotes derived from our 
“therapeutic strain”. To test the incorporation of the mutated alleles and to obtain 
homozygous triple KO mice, a complex strategy was designed as illustrated on Fig 19. 
Briefly, F0 mice were subjected to triple PCR analysis, as well as T7 endonuclease assay 
followed by sub-cloning and sequencing of the DNA fragments for each target. Mice 
positive for T7 assay with a frame shift mutation were selected for breeding. Germline 
transmission of indels was determined from the F1 generation by the same process as in 
the case of the F0. F1 generation was crossed possibly with mice that already incorporated 
mutated alleles of at least one of the target genes. However, extraordinary number of 
crosses were necessary to reach the final desired genotype to study the role of the absence 
of these three genes in PDAC development. After two years, this strain is still under 
generation. 
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Figure 19. Triple knockout mice by CRISPR. The scheme depicts the generation and 
the genotyping strategy of triple mutant mice. SgRNA of Lum, Hp, Msln was injected 
along with Cas9 mRNA into the cytoplasm of zygotes derived from the therapeutic strain 
resulting in F0 knockout mouse generation. PCR strategy was designed to amplify the 
target region. The PCR product was used for T7 endonuclease assay and DNA sequencing 
of subclones to identify indels. Mice with frameshift mutations were selected to generate 
knockout mouse strain by intercrosses. F1 generation was subjected to verify mutations 
with the same strategy. Intercrosses were repeated until the appropriate genotype was 
obtained.  
Table 1 shows the efficiency of each step in the process of triple KO PDAC strain 
establishment. In three microinjection sessions, a total number of 25 pups were born. T7 
assay and sequencing analysis demonstrated various single – and bi-allelic mutational 
events in the F0 generation. In few occasions, even 4 different indels were found per 
target per mouse, such as in the case of Lumican (Table 1). This data suggests possible 
remaining activity of the Cas9 protein during first cell divisions.  
Only 11 mice carried mutations in at least one gene (44%), the rest of the mice 
(56%) were WT. From the 11 mutant mice, 3 contained indels only in 1 target, 6 mice 
carried mutations in 2 genes and 2 triple knockout mice were obtained. However, several 
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mutated alleles were not transmitted to the F1 generation and the final numbers were 
reduced to 4 single, 5 double and 1 triple mutant mice. 
Table 1.  Summary of mutations and efficiency of Triple KO mice. The table shows the 
number of mutated alleles found for each gene in the F0 generation found in each gene 
as well as the number of single, double and triple mutant mice distributed among the 
target genes. The efficiency of each target gene generating mutated mice upon injection 
of the combined sgRNAs is shown in the last column. The efficiency of simultaneously 
mutant mice is depicted in the lower line. 
Gene Max. mutant 
alleles/mouse (F0) 
 Single 
 
Double 
 
Triple 
 
Total Efficiency 
of target 
Lum 4  0 2  
 
  1 
6 24% 
Hp 2  0 2 6 24% 
Msln 2  3 5 10 40% 
Efficiency of mutants  12% 24% 12% 44% 
 
In conclusion, simultaneous deletion of three target genes and generation of a triple 
KO strain by the CRISPR/Cas9 genome editing technology resulted in lower efficiency 
than single mutated KO mice intents. In addition, NHEJ – mediated gene mutations 
produced mutations in a highly unpredictable and rather inefficient manner.  
4.1.3.4 Generation of Saa3 null mice by conventional targeted deletion 
The role of Saa3 in tumor development has not been investigated yet. A germline 
knockout mouse model has been described in the context of obesity-induced 
inflammation (209) with no major effect on normal homeostasis.  
Preliminary results demonstrated pro-tumorigenic effect of this protein when silenced by 
shRNA. Thus, we decided to eliminate Saa3 in our PDAC mouse model. The Saa3 null 
allele was generated by homologous recombination using a BAC vector, where a LacZ 
gene cassette and a Neomycin resistance cassette at the ATG transcription start site 
replaces the entire protein coding sequence (Fig 20 A). The Saa3 null mouse sperm was 
used for in vitro fertilization of KPeCY females. By intercrosses we obtained 
homozygous Saa3 null mice (Fig 20B) at the expected Mendelian ratio and mice were 
healthy as reported before (209). 
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Figure 20. Generation of Saa3 null mice. (A) Scheme of the Saa3 null allele. LacZ 
reporter cassette is at the ATG transcription start site, followed by Neomycin resistance 
cassette (Neo) flanked by loxP sites (triangles). (B) PCR analysis of the Saa3 null allele 
in mouse tail DNA. Lane 1: Saa3-/-; lane 2 and 4 Saa3+/-; lane 3 and 5: Saa3+/+. KO: null 
allele; WT: wild type allele. Expected fragment size of each allele is depicted.  
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4.1.4 Saa3 in mouse PDAC development 
To study the effect of ablating Saa3 expression in PDAC development, we 
incorporated Saa3 null alleles to our PDAC mouse model, the K-
Ras+/LSLG12Vgeo;Trp53lox/lox;Rosa26+/LSLEYFP;Elas-tTA/tetO-Cre,  KPeCY strain.  
4.1.4.1 PanIN formation and survival 
Saa3 null K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice displayed the same number of 
PanIN lesions and PDAC tumors as Saa3 competent animals (Fig 21A). Likewise, 
KPeCY mice carrying either wild type Saa3 alleles (n = 18) or Saa3 null alleles (n = 20) 
developed PDAC with 100% penetrance succumbing to pancreatic tumors before 23 
weeks of age with median survivals of 15 and 16 weeks, respectively. These observations, 
taken together, indicate that the absence of Saa3 expression from their germline has no 
significant effect on tumor development (Fig 21B).  
 
 
Figure 21. PanIN formation and survival. (A) Quantification of low and high grade 
PanIN lesions as well as PDACs in KPeCY mice expressing or lacking Saa3. (B) Kaplan-
Meier survival curve of KPeCY mice expressing (open circle) or lacking Saa3 (closed 
circle). Saa3 WT, open circle; Saa3 null, closed circles.  
4.1.4.2 Stroma reorganization in Saa3 tumors 
Histological analysis revealed that Saa3 null tumor cells were more packed than in 
control tumors and exhibit a significant reorganization of their extracellular matrix as 
revealed by their reduced levels of collagen content (Fig 22A). Saa3 null tumors had a 
higher proportion of EYFP+ tumor cells and displayed less dense fibrotic stroma, albeit 
these differences were not statistically relevant in FACS analysis (Fig 22B). Interestingly, 
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we did not observe a significant reduction in the PDGFRα+ population, indicating that 
the reduced stromal content is not due to the loss of this CAF subpopulation (Fig 22C).  
 
Figure 22. Characterization of the stromal component of Saa3 null tumors. (A) (Left) 
Masson’s Trichrome and Sirius Red staining of collagen in Saa3 competent (WT) and 
Saa3 null (KO) tumors. Scale bar, 50 m. (Right) Quantitative analysis of Masson’s 
Trichrome stained sections of Saa3 competent (WT) and Saa3 null (KO) tumors (n = 4). 
(B) (Left) Quantitative FACS analysis of EYFP+ tumor cells and (Right) Tumor/stroma 
ratio in PDAC tumors of Saa3 competent (solid bars) and Saa3 null (open bars) KPeCY 
mice (n = 6). Tumor/stroma ratio was calculated as the percentage of tumor cells vs. the 
percentage of immune (CD45), endothelial (CD31) and fibroblast (PDGFRα+) 
compartments all together (n = 6). (C) Quantitative FACS analysis of PDGFRα+ cells in 
PDAC tumors of Saa3 competent (solid bars) and Saa3 null (open bars) of KPeCY mice.   
Moreover, we observed a significant increase in the levels of macrophage 
infiltration in the Saa3 null tumors (12,5% vs. 3,8% of total area, Fig 23A). The increase 
in tumor-infiltrating macrophages was observed in both the anti-tumorigenic M1 as well 
as the pro-tumorigenic M2 populations (Fig 23B). However, this increase appeared to be 
more pronounced in the M2 populations, which has been associated with worse clinical 
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outcome in PDAC patients (234). In contrast, there were no obvious differences in the 
amount or localization of neutrophils or T and B lymphocytes (data not shown). Saa3 null 
tumors also displayed a significantly elevated number of endothelial CD31+ cells, 
indicating increased vessel density (Fig 23A). These vessels were functional as assessed 
by the greater perfusion observed upon injection of a contrast agent (Fig 23C). Whether 
increased angiogenesis was promoted by the infiltrating macrophages, as previously 
suggested (235), remains to be determined.  
 
 
Figure 23. Stroma reorganization in Saa3 null tumors. (A) (Left) Representative 
images of F4/80 and CD31 immunostaining in Saa3 competent (WT) and Saa3 null (KO) 
tumors. Scale bar, 50 m. (Right) Quantitative analysis of F4/80 and CD31 stained 
sections of Saa3 competent (WT) and Saa3 null (KO) tumors (n = 5). (B) (Left) FACS 
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analysis of fresh Saa3 competent (WT) and Saa3 null (KO) tumor samples with anti-
F4/80 and anti-CD11b antibodies. (Center) FACS analysis of F4/80+/CD11b+ double 
positive macrophages with anti-CD11c and anti-CD206 antibodies. The percentage of 
M1 (CD11chigh/CD206low) (blue square) and M2 (CD11clow/CD206high) (red square) 
macrophage populations is indicated for each tumor type. (Right) Quantitative analysis 
of M1 and M2 macrophages in Saa3 competent (WT) and Saa3 null (KO) tumors (n = 2). 
(C) (Left) Micro-ultrasound images of Saa3 competent (WT) and Saa3 null (KO) tumors 
after injection of contrast agent. (Right) Quantitative analysis of vessel density in Saa3 
competent (WT) and Saa3 null (KO) tumors (n = 5). (*P < 0.05, **P<0.001 ***P < 
0.001). 
4.1.4.2.1 Stroma remodeling has low impact on treatment efficiency 
Next, we interrogated whether the effect of Saa3 ablation on stroma remodeling 
improved the therapeutic benefit of drug treatments. We reasoned that a reduction in 
fibrosis and increase in functional angiogenesis could increase the efficacy of the standard 
of care therapy, gemcitabine (GEM). We treated control Saa3 expressing and Saa3 null 
KPeCY mice with GEM and vehicle starting when tumors were detected by ultrasound 
and finishing at humane end point. Surprisingly, tumors progressed slightly faster in Saa3 
wild type (n = 7) mice than in Saa3 knockout (n = 5) mice (Fig 24). Interestingly, there 
was a better response to GEM treatment in Saa3 wild type (n = 6) mice than in Saa3 
knockout (n = 5) mice as illustrated by tumor growth (Fig 24A). However, the slight 
increase in survival of Saa3 knockout mice treated with GEM could explain that their 
tumors were bigger at humane end point (Fig 24B).  
Furthermore, we studied the therapeutic strategy of depleting macrophages by 
Clodronate in combination with GEM, since targeting tumor-infiltrating macrophages 
was previously shown to be beneficial in PDAC (50) The effect in tumor growth in Saa3 
knockout (n = 5) mice was highly improved compared to GEM alone. Moreover, in these 
mice a small benefit in relative tumor volume was observed compared with Saa3 wild 
type (n = 4) mice. However, this combination treatment did not enhance significantly the 
survival, maybe due to toxicity (Fig 24B).  
Since PDAC is inherently poorly vascularized antiangiogenic therapies might not 
be beneficial. However, in preclinical trials VEGF inhibition reduced tumorigenicity 
(236). On the other hand, Phase III clinical trials with Gemcitabine alone or in 
combination with Bevacizumab resulted in questionable improvement of overall survival 
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probably due to lack of patient classification (237). Therefore, we tested if there was 
increased therapeutic benefit in Saa3 knockout mice, where angiogenesis is highly 
induced. Indeed, treatment with the antiangiogenic agent (anti-VEGF antibody, 
B20.4.1.1, Genentech) in combination with GEM, displayed better therapeutic outcome 
in Saa3 knockout mice (n = 5) compared to Saa3 wild type mice (n = 6) (Fig 24A). 
Additionally, in both cohorts, mice survived significantly longer compared to vehicle 
treated littermates (Fig 24B).  
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Figure 24. Treatments of tumor-bearing mice. (A) Tumor volume change in Saa3 
competent (solid bars) and Saa3 null (open bars) KPeCY mice after exposure to the 
indicated treatments: Vehicle (n = 5), Gemcitabine (Gem) (n = 5), Gemcitabine + 
Clodronate (n = 5) and Gemcitabine + B20 antibody (n = 4). ns, not significant. 
(B) Kaplan-Meier survival analysis of the same Saa3 competent (solid circles) and Saa3 
null (open circles) KPeCY mice upon treatment.  
4.1.4.3 Undifferentiated tumor phenotype 
4.1.4.3.1 Stem cell-like tumor cells 
Tumors lacking Saa3 appeared less differentiated upon Hematoxylin & Eosin 
(H&E) and CK19 staining (Fig 25A). Undifferentiated tumor phenotype has been 
associated with a cancer stem-like state in pancreatic cancer (238). Therefore, we assessed 
the cancer stem cell compartment (CSC) in Saa3 competent and Saa3 null tumors. As 
illustrated in Figure 25B, we found a marked increase in CSC (CD133+) and metastatic 
CSC (CD133+/CXCR4+) populations in Saa3 competent PDAC tumors versus those 
lacking Saa3 expression (0.56% vs 4.02% CD133+ cells and 0.15% vs 0.43% in 
CD133+/CXCR4+ cells, respectively). These results suggest that the absence of Saa3 
confers a more invasive phenotype (239). Indeed, Saa3 null tumors showed a higher Ki67 
proliferation index (Fig 25C).  
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Figure 25. Undifferentiated Saa3 null tumors. (A) (Top) H&E staining and (Bottom) 
CK19 immunostaining of Saa3 competent (WT) and Saa3 null (KO) tumors. Scale bar, 
50 m. (B) FACS analysis of fresh tumor samples Saa3 competent (WT) and Saa3 null 
(KO) tumors from KPeCY mice with anti-CD133 and anti-CXCR4. (C) Quantitative 
analysis of Ki67 positive cells in Saa3 competent (WT) and Saa3 null (KO) tumor 
sections. 
Moreover, EYFP+ tumor cells present in the pancreas of 8-week old Saa3 null mice 
displayed a considerably higher percentage of PDGFRα+ cells than those expressing Saa3 
(2.43% vs. 0.21%, respectively) (Fig 26A). Since PDGFRα expression is a marker for 
epithelial to mesenchymal transition (EMT), these results suggest that the absence of 
Saa3 expression might promote the appearance of a migratory phenotype (143, 240, 241).  
4.1.4.3.2 Migratory properties – metastasis 
Since PDAC tumor cells most frequently metastasize to the liver we examined the 
presence of Saa3 competent and Saa3 null EYFP+ pancreatic tumor cells in this tissue. 
As illustrated in Figure 26B, we detected an unusually high number of disseminated tumor 
cells in the liver of KPeCY Saa3 null animals, representing as many as 15.3% of all liver 
cells. In contrast, the number of tumor cells in Saa3 competent animals only represented 
0.07% of the liver cell population (Fig 26B and C). 
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Figure 26. Disseminated EYFP+ tumor cells. (A) FACS analysis of EYPF expressing 
PDGFRα+ pancreatic tumor cells in pancreas isolated from 8-week-old Saa3 competent 
(WT) and Saa3 null (KO) KPeCY mice. (B)  FACS analysis of EYPF expressing cells in 
livers isolated from the same mice. (C) Images of GFP staining in livers of Saa3 
competent (WT) and Saa3 null (KO) KPeCY mice sacrificed at 8 weeks old age or 
humane end point (HEP). Scale bar, 100 µm. Insets display high magnification images. 
Scale bar, 30 µm. 
However, these disseminated Saa3 null tumor cells did not proliferate and failed to 
propagate after colonization (Fig 27A). Indeed, whereas 12 out of 63 (19%) Saa3 
competent mice displayed metastatic outgrowths, only 2 out of 40 (5%) Saa3 null animals 
presented metastatic lesion in their livers (P = 0.043) (Fig 27 B). These reduced levels of 
metastatic outgrowth were not due to a reduction in the inflammatory cell population, 
CD11b+ and F4/80+ monocyte derived-immune cells, which are known to establish the 
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metastatic niche (36, 37) (Fig 27C). Thus, this suggest that the reduced metastatic 
potential of Saa3 null tumors is an intrinsic property of the tumor cells. Indeed, these 
infiltrated Saa3 null tumor cells were negative for Ki67 immunostaining, indicating that 
they have limited proliferative properties (Fig 27A). However, it is also possible that 
absence of Saa3 expression in the liver may contribute to the limited proliferative and 
metastatic properties of these tumor cells. 
It has been reported that Saa1 is a potent inducer of liver metastasis (191). In 
addition, SAA1 is among the top 50 upregulated genes in metastatic liver expression 
profile in a human PDAC dataset analyzed by Moffitt et al., suggesting that SAA1 may 
be relevant in liver metastasis formation (72). Thus, we examined the levels of expression 
of other Saa family members in livers of Saa3 competent and Saa3 null tumor bearing 
mice sacrificed at humane end point. As illustrated in Fig 27D, the levels of expression 
of Saa1 and Saa2 are high in the livers of Saa3 competent, but not in Saa3 null tumor 
bearing mice. These results may also contribute to explain why the abundant pancreatic 
tumor cells present in the livers of Saa3 null mice have limited metastatic potential.  
 
Figure 27. Metastatic properties of Saa3 null mice. (A) Co-staining of GFP (brown) 
and Ki67 (magenta) to mark EYFP+ tumor cells that proliferate (Ki67+) on liver sections 
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of 8 weeks old Saa3 null KPeCY mice. Scale bar 50 µm. (B) Incidence of metastasis in 
tumor-bearing mice sacrificed at humane end point. (C) FACS analysis of the 
macrophage population in livers of 8-week-old Saa3 competent (WT) and Saa3 null (KO) 
KPeCY mice with F4/80 and CD11b antibodies (n = 4). (D) Expression analysis by qPCR 
of Saa family members in livers of Saa3 competent (Saa3 WT) (n = 3) and Saa3 null 
(Saa3 KO) (n = 3) tumor bearing KPeCY mice sacrificed at HEP and in WT control livers 
(n = 2). Saa1 (solid bars), Saa2 (open bars) and Saa3 (red bars) are indicated. 
To better characterize the effect of Saa3 ablation on the migratory properties of 
PDAC tumor cells, we generated cell lines from pancreatic tumors lacking this protein. 
FACS analysis confirmed that the number of CD133+/CD44+ CSCs was higher in Saa3 
null EYFP+ tumor cell lines (46.6% vs. 18.8%) (Fig 28A) demonstrating a clear 
enrichment in this population (239). Migration assays revealed that tumor cells lacking 
Saa3 displayed increased migratory properties (Fig 28B). While Saa3 expressing tumor 
cells advanced towards the scratch as a solid layer, cells lacking Saa3 moved freely 
throughout the scratch as individual cells (Fig 28B). CAFs lacking Saa3 expression also 
had increased motility and closed the gap more efficiently than those expressing the 
protein (61,5% in Saa3 null vs. 40.8% in wild type CAFs in a 16 hr period) (Fig 28C).  
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Figure 28. In vitro migratory cells. (A) FACS analysis of pancreatic tumor cell lines 
with anti-CD133 and anti-CD44. (B) Migratory properties of Saa3 competent (WT) and 
Saa3 null (KO) tumor cells in an in vitro scratch assay. The right panel depicts a color 
enhanced picture for better visualization. (C) Quantitative analysis of migration assays in 
Saa3 competent (WT, solid bar) and Saa3 null (KO, open bar) CAFs. The percentages 
represent the area covered by CAFs in 16 hours after the generation of the scratch.  
4.1.4.4 Anti-tumorigenic properties of Saa3 null CAFs 
Germline elimination of Saa3 did not induce significant survival benefit in PDAC 
mouse model. However, CAF specific knock-down of Saa3 previously showed reduction 
in tumor size upon co-injection with tumor cells subcutaneously into the flanks of nude 
mice (Fig 10). To study further the anti-tumorigenic properties of CAFs lacking Saa3 we 
isolated CAFs from tumor bearing Saa3 null KPCY mice by cell sorting using PDGFRα 
and established primary Saa3 null CAF cell lines. 
4.1.4.4.1 Organoid co-culture of Saa3 competent and null CAFs and tumor cells 
To characterize the effect of Saa3 on the interaction between pancreatic tumor cells 
and CAFs in vitro, we examined the growth properties of organoids generated from 
PDAC tumors of KPCY mice co-cultured with CAFs expressing or lacking Saa3. As 
illustrated in Figure 29A, Saa3 expressing CAFs significantly increased the number and 
size of individual organoids (Fig 29B). In contrast, Saa3 null CAFs failed to promote 
tumor growth resulting in organoid cultures similar to those grown in the absence of 
CAFs. As expected, NPFs effectively reduced the growth of organoids (Fig 29A and B). 
These results clearly indicate that Saa3 plays a key role on the ability of CAFs to support 
tumor cell growth. 
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Figure 29. Anti-tumorigenic properties of Saa3 null CAFs in vitro. (A) Cultures of 
EYFP+ tumor organoids grown in the presence of NPFs, Saa3 competent (WT) and Saa3 
null (KO) CAFs. Scale bar, 100 m. (B) Quantification of (Left) area and (Right) number 
of organoids under the indicated cultured conditions. 
4.1.4.4.2 Orthotopic allografts of Saa3 competent and null CAFs and tumor cells 
To explore the effect of Saa3 in the cross-talk between tumor cells and CAFs in 
vivo, we inoculated orthotopically in immunocompromised mice CAFs as well as tumor 
cells (0.5x106 each) either expressing or lacking Saa3 (Fig 30A). As illustrated in Figure 
24B, ablation of Saa3 in tumor cells (n = 6) had no effect on their ability to induce tumors. 
As expected, based on the results described above using in vitro assays, co-injection of 
Saa3 expressing tumor cells with NPFs (n = 6) reduced tumor growth whereas co-
injection with Saa3 expressing CAFs (n = 8) led to a significant increase in tumor volume. 
Interestingly, when these tumor cells were co-injected with CAFs lacking Saa3 (n = 8), 
tumor growth was significantly reduced to levels even lower than those observed with 
NPF, indicating that Saa3 is essential for the ability of CAFs to stimulate tumor growth 
in vivo. However, this effect was not observed when we co-injected Saa3 null tumor cells 
along with Saa3 null (n = 6) CAFs (Fig 30B). No significant differences were observed 
in the proliferation (Ki67) or apoptosis (cleaved Caspase 3) levels that could explain the 
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differences in tumor volume induced by Saa3 competent versus Saa3 null CAFs (Fig 
30C). These observations indicate that whereas Saa3 provides pro-tumorigenic properties 
to CAFs, the anti-tumorigenic effect of Saa3 null CAFs requires that the corresponding 
tumor cells express the Saa3 protein. Likewise, we also observed a pro-tumorigenic effect 
when we co-injected Saa3 null tumor cells with Saa3 null CAFs, suggesting that when 
both cell types are deficient in Saa3 expression there is an alternative cross-talk that 
promotes tumor progression. These results provide an explanation as of why tumor 
development in Saa3 null mice is not affected, since the potential tumor inhibitory effect 
of Saa3 ablation in CAFs does not take place when their neighboring tumor cells also 
lack Saa3.  
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Figure 30. Anti-tumorigenic properties of Saa3 null CAFs in vivo. (A) Diagram 
depicting the in vivo orthotopic tumor assays in immunodeficient mice carried out to 
determine the pro-tumorigenic properties of Saa3 competent (WT) (red) and Saa3 null 
(KO) (light blue) CAFs on pancreatic tumor cells isolated from Saa3 competent (WT) 
(yellow) and Saa3 null (KO) (green) tumors. (B) Quantitative analysis of orthotopic 
tumor growth in immunodeficient mice inoculated with the indicated combinations of 
Saa3 competent (WT) and Saa3 null (KO) CAFs and pancreatic tumor cells. Colors used 
to represent the corresponding bars are those indicated in (B). NPFs (open bar) were used 
as a negative control. (C) Immunohistochemical representation of apoptosis (Cleaved 
Caspase 3 and proliferation (Ki-67) of orthtotopic tumors. (***P < 0.001).  
Taken altogether, in the following table we summarize the most important findings 
obtained with the Saa3 null PDAC mice.  
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Table 2. Most relevant features of Saa3 competent and Saa3 null KPeCY mice. 
Grading of the phenotypes is illustrated from not observed (–) to low (+), normal (++), 
high (+++), or very high (++++). 
 
4.1.4.5 Transcriptional profiling of Saa3 null cells 
4.1.4.5.1 Comparative expression profile of Saa3 null and competent CAFs 
To dissect the mechanism by which Saa3 confers tumor stimulatory properties to 
CAFs, we used RNAseq to compare the transcriptome of Saa3 null and Saa3 proficient 
CAFs. GSEA pathway analysis of Saa3 null CAFs revealed a significant enrichment in 
Proliferation and Angiogenesis hallmarks, as well as upregulation of Sonic Hedgehog, 
TNF-α NF-B and IL-6 pathways. Moreover, we observed enrichment in genes 
implicated in EMT, suggesting increased plasticity of Saa3 null CAFs as well as their 
potential effect in inducing an undifferentiated phenotype in their neighboring tumor cells 
(242). In addition, the Saa3 null CAFs displayed upregulation of the Apical Junction 
pathway, a property that predicts increased physical contact between stromal and tumor 
cells (224). Finally, Saa3 null tumor cells displayed upregulation of the Tight Junction 
pathway suggesting increased cell-to-cell contact properties (Fig 31).  
The most downregulated gene sets included the Oxidative Phosphorylation and 
Drug Metabolism pathways (Fig 31). Moreover, loss of Saa3 expression also 
downregulated other metabolic pathways such as Glycolysis. This pathway is activated 
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in Saa3 competent CAFs possibly playing a role to provide metabolites to their 
neighboring tumor cells (148). These observations suggest that loss of Saa3 might induce 
metabolic reprogramming of CAFs along with a reduction in the production of nutritional 
metabolites available to the adjacent tumor cells.  
 
Figure 31. Transcriptional profiling of Saa3 KO CAFs. GSEA pathway analysis of 
Saa3 null vs. Saa3 proficient CAFs. The Normalized Enrichment Score (NES) ranking 
was generated by the GSEA. 
4.1.4.5.2 Comparative expression profile of Saa3 null and competent tumor cells 
We also interrogated of the transcriptomes of Saa3 competent and Saa3 null tumor 
cells (Fig 26). This analysis revealed that loss of Saa3 expression in pancreatic tumor 
cells results in a significant enrichment of cell cycle and metabolism related gene sets. 
Thus, confirming the increased proliferative capacity of the Saa3 null tumor cells. In 
addition, these mutant tumor cells displayed upregulation of the Tight Junction pathway 
suggesting increased cell-to-cell contact properties. On the other hand, we observed 
significant downregulation in ECM reorganization related pathways, suggesting a 
decrease in the levels of extracellular collagen, a feature that might explain the higher 
migratory properties of Saa3 null tumor cells (Fig 26).  
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Figure 32. Transcriptional profiling of Saa3 KO tumor cells. GSEA pathway analysis 
of Saa3 null vs. Saa3 proficient CAFs. The Normalized Enrichment Score (NES) ranking 
was generated by the GSEA. 
4.1.4.5.3 Cytokine profiles 
Saa3 is involved in the regulation of several inflammatory cytokines (191, 243). 
Thus, we examined the profile of cytokine enrichment changes by GSEA analysis 
utilizing a specific signature of 144 cytokines. As illustrated in Figure 33, elimination of 
Saa3 downregulated global cytokine profile not only in CAFs but also in the tumor cell 
compartment (Fig 33). These results suggest that elimination of this inflammatory protein 
has an important role in the regulation of inflammatory cytokines and probably in 
systemic inflammation.  
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Figure 33. Cytokine profiles of Saa3 competent and null cells. Specific cytokine 
signature was found significantly downregulated in both Saa3 null CAFs (FDR = 0.03) 
and in Saa3 null tumor cells (FDR = 0.01) by GSEA analysis. Enrichment score was 
generated by the GSEA software. 
Taken together, transcriptome profiling result of Saa3 null cells indicate that 
elimination of Saa3 induces proliferation, metabolic reprogramming and cell-to-cell 
contact in both CAFs and tumor cell population. On the other hand, lack of Saa3 reduces 
overall cytokine secretion with the exception of the TNF-α and IL-6 pathways in CAFs. 
4.1.4.5.4 Mpp6 – Saa3 axis 
Differential expression analysis of the above data set revealed the presence of three 
significantly upregulated genes in Saa3 null CAFs. In particular, the gene encoding the 
Membrane Palmitoylated Protein 6 (Mpp6) (fold change = 15.8), a member of the 
palmitoylated membrane protein subfamily of peripheral membrane-associated guanylate 
kinases (MAGUK) (Fig 34A and B). The other upregulated genes included those encoding 
the g-aminobutiric acid receptor 3 (Gabra3, fold change = 3.2) and Cbl, an E3 ubiquitin-
protein ligase involved in cell signaling and protein ubiquitination (fold change = 2.3) 
(Fig 34A). These observations were validated for Mpp6 using qRT-PCR analysis of Saa3 
null and competent CAFs (Fig 34C).  
To determine whether Mpp6 upregulation was functionally involved in the anti-
tumorigenic effect of Saa3 null CAFs, we knocked down Mpp6 expression using specific 
shRNAs that resulted in a significant decrease of its expression levels. Mpp6-
downregulated Saa3 null CAFs were co-injected orthotopically with Saa3 competent 
PDAC tumor cells. These tumor cells grew significantly faster than those co-injected with 
Saa3 null CAFs reaching proliferation levels similar to those observed with Saa3 
competent CAFs (Fig 34D). Downregulation of Mpp6 also reverted the undifferentiated 
phenotype of tumor cells in the presence of Saa3 null CAFs (Fig 34D). These 
observations, taken together, indicate that the growth inhibitory activity of Saa3 null 
CAFs on their adjacent tumor cells is mediated by the upregulation of the tight junction 
protein Mpp6. Interestingly, Saa3 ablation did not alter the levels of expression of Mpp6 
in pancreatic tumor cells (Fig 34B) indicating that Saa3 selectively controls the expression 
of Mpp6 in CAFs.  
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Figure 34. Identification and downregulation of Mpp6 in Saa3 null CAFs. (A) Heat 
map of the differentially expressed genes in Saa3 null (KO) CAFs compared to Saa3 
competent (WT) CAFs. (B) RNAseq analysis of Mpp6 expression in Saa3 competent 
(WT, solid bars) and Saa3 null (KO, open bars) CAFs and tumor cells. (C) qPCR 
validation of Mpp6 expression levels in NPFs (open bar), Saa3 competent (WT) and Saa3 
null (KO) CAFs (grey bar). (D) Tumor growth of orthotopic allografts of 
immunocompromised mice of Saa3 competent (WT) and Saa3 null (KO) pancreatic 
tumor cells in the presence of Saa3 competent (WT) and Saa3 null (KO) CAFs treated 
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(+) or non-treated (–) with a shRNA against Mpp6. Tumor volume is indicated by solid 
(WT cells), open (KO cells) and mixed solid/open (WT and KO cells) bars. (E) H&E and 
CK19 staining images of orthotopic tumors obtained from (E). Scale bar, 100 m. 
(**P<0.001). 
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4.1.5 SAA1 in human PDAC 
The human genome contains three genes encoding highly related SAA family 
members (40% amino acid identity), SAA1, SAA2 and SAA4 (244). It also contains a 
non-functional SAA3 pseudogene (SAA3P) (183). Among the three SAA functional genes, 
SAA1 is the most similar in structure and function to murine Saa3. The SAA1 protein is 
expressed in several stromal cell types including activated synovial fibroblasts (194). 
Moreover, SAA1 has been shown to control neutrophil plasticity and has anti- and pro-
tumorigenic inflammatory properties in melanoma (245). SAA1 is highly expressed in a 
variety of tumors including PDAC (TCGA database).  
4.1.5.1 Gene expression profiling of human CAFs 
To validate our findings in human disease, we isolated hCAFs and hNPFs from 
PDAC patient samples and adjacent normal tissues by outgrowth method (155). We 
compared their expression profile by RNAseq and verified significant enrichment 
between human and mouse CAF expression profiles shown by GSEA analysis (Fig 35A). 
Indeed, the most upregulated gene sets were Cytokine-Receptor Interaction and 
Complement Cascade pathways in hCAFs compared to hNPFs, similar to our observation 
in mouse CAFs.  
Next, we examined the expression levels of all SAA family members in our RNA 
seq dataset, which revealed SAA1 with the highest expression in hCAFs (Fig 35B). We 
validated these results by qPCR in primary CAF samples and observed distinct expression 
values of SAA1 suggesting variability among CAF samples (Fig 35B). 
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Figure 35. RNAseq analysis of human CAFs. (A)(Left) Comparison of mouse and 
human fibroblast signatures by GSEA analysis. Genes that were upregulated in mouse 
CAFs were downregulated in hNPFs. (Right) Upregulated pathways in hCAFs shown by 
GSEA pathway analysis. (B)(Left) Expression levels of SAA family members: SAA1, 
SAA-like 1 (SAA1L) SAA2, SAA3 pseudogene (SAA3P) and SAA4. Values are 
displayed in normalized FPKM derived from RNAseq results. (Right) Validation of 
SAA1 expression levels by qPCR in different primary hCAFs.  
4.1.5.2 Analysis of SAA1 in the DKFZ human PDACdata set 
Since gene expression signatures can be altered during cell culture we decided to 
analyze cellular populations isolated by cell sorting, similarly to the method we utilized 
for mouse samples. Hence, we established a collaboration with the group of Andreas 
Trumpp (DKFZ). This group has an unpublished dataset obtained from freshly isolated 
CAFs from tumor samples of PDAC patients (n = 7) and from adjacent normal pancreas 
(n = 5). The analysis of his data set revealed that SAA1 is upregulated in the CAF samples 
compared to those obtained from normal pancreata (log2 fold change = 3.74; P<0.005). 
In contrast, the levels of MPP6 expression were lower in CAFs than in normal pancreatic 
fibroblasts (Fig 36A). That is, the levels of both genes, SAA1 and MPP6, inversely 
correlated in both types of fibroblasts (Fig 36B). 
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Figure 36. SAA1 in human sorted fibroblasts in DKFZ dataset. (A) (Top) SAA1 and 
(Bottom) MPP6 expression in freshly sorted human NPFs (n = 5) (open bars) and CAFs 
(n = 7) (solid bars). (B) Correlation of SAA1 and MPP6 expression in freshly sorted 
human CAFs (n = 7, solid circles) and human NPFs (n = 5, open circles). Spearman 
Correlation (Corr) and P value are indicated. (*P < 0.05, **P<0.001). 
4.1.5.3 Analysis of the Moffitt human PDAC data set 
To further confirm these observations, we examined the SAA1 expression levels in 
the PDAC RNAseq and microarray data set recently published by Moffitt and coworkers 
(72). RNAseq data revealed high but variable expression of SAA1 both in tumors and in 
CAFs isolated from PDAC samples (Fig 37A). Moffitt´s report described two types of 
PDAC-associated stroma, “normal” or “activated”, based on stromal signatures 
considering high αSMA expression or an inflammatory signature, respectively (72). 
Although, SAA1 was primarily found expressed in tumor samples with “activated” stroma 
signature, high levels of SAA1 expression correlated with significantly worse survival in 
both tumor samples containing “normal” or “activated” stroma (Fig 37B). In those tumor 
samples that contained low amounts of stroma, high SAA1 expression correlated with a 
slight increase in survival, suggesting that the pro-tumoral effect of SAA1 overexpression 
is primarily mediated by the stromal cells. In addition, SAA1 was identified among the 
top 50 genes of liver specific metastatic PDAC signature in Moffitt´s analysis. These 
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results support the concept that SAA1 may play a role in human PDAC similar to that 
described for Saa3 in mouse tumors. Similarly, as shown in the previous dataset, SAA1 
expression negatively correlated with MPP6 levels in PDAC stroma (Fig 37C). 
 
Figure 37. Analysis of the Moffitt dataset. (A) Fragments Per Kilobase Million (FPKM) 
values of SAA1 expression by RNAseq in human CAFs and PDAC samples obtained 
from Moffitt´s dataset (72). (B) Kaplan-Meier survival analysis of PDAC patients with 
high (red) or low (blue) SAA1 expression levels classified by the presence of (Top) 
activated or (Middle) normal stroma signatures as well as in (Bottom) PDAC tumors with 
low stroma content based on microarray data from Moffitt´s dataset (72). (C) Correlation 
of SAA1 and MPP6 expression and human PDAC stroma signatures. Spearman 
Correlation = -0.28 with P value = 0.02.  
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5 Discussion 
5.1 Targeting the stroma in PDAC by reprogramming CAFs 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer, due to the inefficient 
current therapeutic strategies. PDAC is characterized by a rich desmoplastic stroma 
mainly composed by a heterogeneous population of cancer-associated fibroblasts (CAFs). 
CAFs contribute to promote cancer progression, immune-suppression and to treatment 
resistance (222). Targeting the stroma has gained interest with the aim to enhance drug 
delivery or inhibit its role in cancer cell chemoresistance or immune-suppression.  
In contrast to the previous concept that pancreatic tumor stroma is solely tumor 
promoting (246), certain components, such as myofibroblasts can function in tumor 
suppression (152). However, this property may be highly dependent on tumor stage, 
tissue context and composition of the microenvironment. Indeed, elimination of 
proliferating SMA myofibroblasts resulted in more aggressive tumors (170). Similarly, 
reduction of fibrotic stroma by genetic inhibition of stroma related Hedgehog pathway 
promoted tumor progression (51). On the contrary, blockade of stroma derived soluble 
factors (87), as well as Vitamin D mediated reprogramming of CAFs resulted in decreased 
tumor volume and increased chemotherapy efficacy. Interestingly, other studies have 
shown that normal fibroblasts have oncogenic suppressive potential  (247, 248). 
Inhibitory property of normal tissue fibroblasts on tumor growth was reported earlier in 
various organs via governing epithelial homeostasis and proliferative quiescence (149, 
150). This suggests that, normal fibroblasts could act as tumor suppressors, a function 
that is lost upon reprogramming to become CAFs.  
Thus, we hypothesized that reprogramming of CAFs to become phenotypically 
closer to normal pancreatic fibroblast (NPF) characteristics, will retain cancer promotion 
and will not have the negative effects of stroma elimination.  
5.1.1 Isolation and gene expression profiling of CAFs 
To confirm our hypothesis, we isolated CAFs and NPFs by two different methods, 
by outgrowth and by cell sorting, and compared their expression profile in order to better 
understand their role in tumor development. Differential expression study identified 117 
commonly upregulated genes in the two CAF populations. Nevertheless, among the most 
upregulated genes we found several of them belonged to the acute-phase response 
proteins, where Serum amyloid A3 presented the highest expression levels. Moreover, 
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GSEA analysis displayed numerous pathways shared by these two CAF populations 
including Complement Cascade as the most significantly upregulated one, as well as 
Cytokine-Receptor Interaction and Innate Immune Response related pathways, such as 
NFB. However, it has to be taken into consideration that CAFs isolated by outgrowth 
method do not represent a pure fibroblast population and may undergo gene expression 
alterations affected by culture conditions. This can explain the discrepancies between the 
differential expression analysis of CAFs isolated by outgrowth vs cell sorting.  
Hence, we decided to further characterize PDGFRα+ subpopulation of CAFs to 
avoid contamination by other cell types and to study a more physiological scenario of 
freshly isolated CAFs.  
5.1.2 PDGFRα+ CAFs are protumorigenic 
A CAF subpopulation expressing PDGFRα is thought to mediate an inflammatory 
response (140). However, their putative pro-tumorigenic activity has not been properly 
documented. In this study, we show that PDGFRα+ CAFs possess pro-tumorigenic 
properties in vivo based on their ability to promote growth of co-injected pancreatic tumor 
cells in immunocompromised mice. This property is specific for PDGFRα+ fibroblasts 
isolated from PDAC tumors since the corresponding PDGFRα+ fibroblasts isolated from 
normal pancreata inhibited tumor growth (Fig 38).  
Recent studies have described distinct populations of CAFs (127, 130, 162). A 
subpopulation, designated as myCAFs, is characterized by elevated expression of αSMA 
and appear to localize immediately adjacent to the neoplastic cells. A distinct 
subpopulation, iCAFs, located more distantly from the neoplastic cells and express low 
levels of αSMA. Instead, these cells display higher levels of secreted IL-6 as well as of 
other inflammatory mediators (162).  
The CAFs isolated in our study, based on the expression of PDGFRα, also have 
high levels of IL-6, suggesting that they may represent iCAFs. Other similarities between 
these iCAFs and the PDGFRα+ CAFs isolated here include significant upregulation of 
cytokine/chemokine-receptor signaling pathways, as well as JAK-STAT signaling. 
However, the PDGFRα+ CAFs characterized in this study display significant 
overexpression of innate immune response-related signaling and high enrichment in cell-
to-cell junction pathways, two properties not reported for iCAFs. Thus, it is plausible that 
the PDGFRα+ CAFs described here might represent, as yet another subpopulation of 
inflammatory CAFs. 
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5.1.3 Target selection validation in CAFs 
We selected and validated candidate genes that fulfilled our criteria in PDGFRα+ 
CAFs and NPFs. Among those, druggability, significant overexpression in CAFs but no 
or low expression in NPFs; functional relevance in PDAC development, as well as in 
human disease were the more important for selection. Validation of overexpression of 
candidate genes in CAFs by qPCR narrowed down our list, which finally resulted in the 
selection of the following genes: Saa3, Has1, Lumican, Haptoglobin and Mesothelin. For 
all of these genes, overexpression has been reported in cancer (175, 227, 229). Some of 
them were found expressed in tumor cells as well (227, 249). Saa3 and Hp are acute-
phase response inflammatory proteins associated to chronic inflammation (198, 226). 
These two genes appeared among the top 25 upregulated genes in inflammatory CAFs of 
mouse PDAC in a recent study by Ohlund et al (162). Lum and Has1 have important role 
in fibrosis and ECM remodeling (232), the latter is responsible for producing hyaluronic 
acid, the matrix component that defines structure and physical properties of the stroma 
(124). Whereas, Mesothelin is a tumor antigen and is proposed as a reliable marker of 
pancreatic cancer, its function has not been addressed properly. We hypothesized, that 
functional studies of these genes would help to better understand to role of CAFs in 
PDAC development either in immunosuppression or in physically induced therapy 
resistance. 
5.1.3.1 Functional validation of targets by RNAi silencing  
shRNA mediated knock down of these targets revealed functional role of the 
selected target genes in tumor stroma crosstalk. We co-injected tumor cells with CAFs, 
in which expression of either Saa3, Has1 or Lumican was downregulated, as well as CAFs 
infected with control shRNA, subcutaneously in the flanks of immunodeficient mice. 
Tumor growth monitoring exhibited reduction in tumor size for all the three genes 
silenced in CAFs compared to CAFs treated with control shRNA. However, the 
differences were not significant. One explanation could be the low efficiency of the knock 
down by shRNA. On the other hand, we did not find a candidate for which silencing 
would enhance pro-tumorigenic activity of CAFs. Further experiment for overexpression 
of these proteins should be performed in order to ensure the significance of these result. 
5.1.3.2 Generation of knockout mouse models by CRISPR in PDAC stroma 
To further investigate to role of the selected genes in PDAC development we took 
advantage of the novel and fast gene editing technology, CRISPR/Cas9, and generated 
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knockout mouse models. By this method, it is also possible to induce mutations 
simultaneously and efficiently ablate genes at the same time.  
We injected guide RNA of Has1 into one cell state embryos derived from our 
“therapeutic strain”, which resulted in 4 knockout chimeras with the ability to transmit 
the modification germ line. However, several crosses were utilized in order to finalize a 
mouse strain for characterization. In addition, multiple mutational events and their 
identification has to be taken into consideration when using CRISPR/Cas9 system. 
Nevertheless, these events occurring through DNA repair mechanism, are not entirely 
sure to result in knockout mutations. Taken altogether, development of single mutated 
Has1 knockout mouse model resulted in 44% efficiency.  
Next, we challenged the capacity of the system, to generate triple mutant mice to 
eliminate Lumican, Haptoglobin and Mesothelin at the same time. Indeed, the three 
sessions of microinjection resulted in 25 chimeras born, from which 3 were single-, 5 
double- and 2 triple-mutant mice that were able to transmit the modification to the next 
generation. However, numerous crosses were necessary to reach the final genotype for 
characterization. This is due to the problem that NHEJ – mediated gene modifications 
produced mutations in a highly unpredictable and rather inefficient manner. Therefore, 
this mouse strain is still under generation, however preliminary data shows normal 
viability when eliminating these genes. Future studies will address the functional role of 
these genes in PDAC development.  
5.2 Saa3 is protumorigenic in CAFs but not in tumor cells 
Transcriptome analysis of the PDGFRα+ CAFs studied here revealed a series of 
selectively upregulated genes when compared with those fibroblasts present in normal 
pancreata. The top-scoring gene was Saa3, a member of the gene family encoding Saa 
proteins (Fig 38). In humans, SAA1 and SAA2 are secreted during acute phase of 
inflammation and have been implicated in several chronic inflammatory diseases, such 
as rheumatoid arthritis, atherosclerosis and amyloidosis. Another member of this gene 
family, SAA3, is not expressed in human cells but has been shown to be a major acute 
phase reactant in other species such as rabbits and rodents (250). Murine Saa3 has been 
shown to be expressed in macrophages (251) and adipose tissue (252). During 
inflammatory processes, Saa3 expression is effectively induced by Il-1β, TNF-α and Il-6 
through NF-κB signaling. Interestingly, these cytokines as well as the NFB pathway 
were found to be significantly upregulated in our CAF dataset.  
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5.2.1 Complete elimination of Saa3 did not affect overall PDAC development 
Germline elimination of Saa3 had no effect of PDAC development as reflected by 
the similar number of lesions observed in Saa3 null mice as well as by the lack of benefit 
in survival. However, Saa3 null tumors exhibit stroma remodeling including reduced 
fibrosis and ECM, infiltrating macrophages and increased vessel density (Fig 38). Indeed, 
Saa3 null CAFs had an elevated Angiogenesis signature as revealed by GSEA pathway 
analysis. It has been suggested that increased vessel density along with a reduction in 
fibrosis may improve the efficacy of chemotherapy treatments (124, 151, 163). However, 
we did not observe a significant increase in the therapeutic benefit of tumor-bearing Saa3 
null mice treated either with Gemcitabine alone.  
Since PDAC is inherently poorly vascularized antiangiogenic therapies might not 
be beneficial. However, in preclinical trials VEGF inhibition reduced tumorigenicity 
(236). On the other hand, Phase III clinical trials resulted in questionable improvement 
of overall survival probably due to lack of patient classification (237). Therefore, we 
speculated whether there would be increased therapeutic benefit in Saa3 knockout mice, 
where angiogenesis is highly induced, when treating mice with Gemcitabine and anti-
VEGF monoclonal antibody. Indeed, Saa3 null mice responded slightly better to this 
combination than Saa3 competent KPeCY mice. Of note, mice in both cohorts lived 
longer upon this combination treatment.  However, the low number of mice in the study 
could be the reason for the non-significant differences. The other possible explanation is 
the effect of the infiltrating pro-tumorigenic M2 macrophages that may have provoked 
therapy resistance. Reduction of gemcitabine induced apoptosis by TAMs in PDAC have 
been reported earlier (153). 
To investigate whether TAMs are the source of the more aggressive Saa3 null 
tumors and of the resistance to treatment we depleted macrophages with Clodronate and, 
at the same time, treated the mice with Gemcitabine. However, while tumor volume 
change was diminished mice died at similar time compared to the control arm, probably 
due the toxicity of the treatment.  
In conclusion, increasing the number of treated mice and further analysis of these 
tumor samples could help to understand the mechanism of therapy resistance induced by 
the tumor stroma in PDAC. 
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5.2.2 Saa3 null tumor cells have increased migratory but not homing properties 
Saa3 null tumors were also less differentiated and more invasive, as suggested by 
a higher proliferation index and increased numbers of pancreatic CD133+ cancer stem 
cells (239). In addition, Saa3 null tumor cells showed an enhanced migratory phenotype 
(Fig 38). We observed an unexpected abundance of Saa3 null tumor cells in the liver 
during the early stages of pancreatic tumor development, constituting as much as 15% of 
all liver cells. We also identified a group of PDGFRα expressing tumor cells in the 
pancreas of the same mice. PDGFRα+ expression on tumor cells was recently 
demonstrated to drive invasive and migratory phenotypic changes in papillary thyroid 
cancer (241). However, these migrating tumor cells did not elicit metastatic outgrowths 
(Fig 38), possibly due to their observed lack of proliferative capacity within the Saa3 null 
liver microenvironment. Whether this migratory phenomenon is due to an intrinsic 
property of the Saa3 null tumor cells or it is a consequence of the absence of this protein 
in liver tissue and/or in pro-metastatic macrophages, remains to be determined. 
Interestingly, we observed that the absence of Saa3 in liver tissue of tumor bearing mice 
inhibits expression of the Saa1 and Saa2 isoforms. Since SAA1 has been described as a 
potent inducer of liver metastasis (7, 26), the reduce levels of expression of Saa1/Saa2 in 
Saa3 null livers could explain why the abundant disseminated pancreatic tumor cells 
cannot form metastatic foci. Conditional ablation of Saa3 expression in specific cell 
populations including tumor cells, CAFs, macrophages and possibly other immune cells 
should help to better define the role of Saa3 during the various stages of tumor 
development. 
5.2.3 Saa3 is required for the pro-tumorigenic properties of CAFs but not for 
tumor cells 
Orthotopic co-injection of Saa3 null CAFs with Saa3 competent tumor cells in the 
pancreas of nude mice significantly reduced tumor size (Fig 38). The inhibitory effect of 
Saa3 null CAFs was even more pronounced than that induced by NPFs. However, this 
inhibitory effect was not observed when we used Saa3 null tumor cells. Since loss of 
Saa3 expression had no significant effect on the tumorigenic properties of pancreatic 
tumor cells, the observed lack of anti-tumorigenic effect of Saa3 null CAFs on Saa3 null 
tumor cells must be due to a defective cross-talk between Saa3 null tumor cells and Saa3 
null CAFs. These results were also observed in vitro using tumor organoids, ruling out a 
putative role of a third cellular partner in this cross-talk. These reconstruction experiments 
DOI:10.14753/SE.2018.2172
  
 
106 
recapitulate the results obtained with Saa3 null mice in which both CAFs and tumor cells 
are devoid of Saa3. Thus, explaining why PDAC development is unaffected in Saa3 null 
mice. Taken together, these results underscore the critical role for Saa3 in mediating the 
interaction between CAFs and tumor cells and predict that selective elimination of Saa3 
in CAFs might provide significant therapeutic benefit. Future studies using conditional 
ablation of Saa3 should help to better define the pro-tumorigenic role of Saa3 in CAFs. 
Besides, inhibition of Saa3 by monoclonal blocking antibody in established tumors could 
also shed light on whether Saa3 has a role in epithelial cells in early stages of tumor 
development.  
Comparative transcriptional profiling of tumor cells and CAFs expressing or 
lacking Saa3 revealed that Saa3 null cells display an increased proliferative signature, 
metabolic reprogramming and could suggest altered heterotypic cell-to-cell contact. 
Moreover, Saa3 deficient CAFs show reduced overall cytokine secretion with the 
exception of the TNF-α and IL-6 pathways. This result was unexpected since acute-phase 
SAA apolipoproteins have been reported to enhance the expression of inflammatory 
cytokines including IL-1β, IL-6, TNF-α, IL-8 and G-CSF. Likewise, pro-inflammatory 
cytokines such as IL-1β, IL-6, and TNFα induce the synthesis of these SAA proteins 
(253). Therefore, upregulation of TNF-α, NF-κB and IL-6 pathways may result from an 
effort by the Saa3 null cells to induce expression of Saa3 thereby generating an 
inflammatory loop. Finally, the reduction of glycolysis and the downregulation of 
cholesterol homeostasis in Saa3 null CAFs, shown by GSEA pathway analysis, could 
contribute to their inhibitory activity on tumor cells observed in orthotopic co-injection 
experiments, by reducing nutrient transport. Similarly, recent results showed metabolic 
reprograming of PDGF induced CAFs by switching from oxidative phosphorylation to 
glycolysis and to support tumor cells with nutrients (148).  
Comparative analysis of Saa3 competent and Saa3 null CAFs revealed minor 
changes in their transcriptome. Yet, we identified three overexpressed genes in Saa3 
deficient CAFs. Of particular interest was Mpp6, a member of the peripheral MAGUK 
family of proteins primarily involved in controlling epithelial cell polarity (254). Mpps 
also function in tumor suppression and receptor clustering by forming multiprotein 
complexes containing distinct sets of transmembrane, cytoskeletal, and cytoplasmic 
signaling proteins (255).  
Interestingly, Mpp6 overexpression appears to be responsible for the loss of pro-
tumorigenic effect of Saa3 null CAFs (Fig 38). Indeed, knock down of Mpp6 expression 
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in these mutant CAFs restored their pro-tumorigenic properties as determined in co-
injection studies with Saa3 proficient pancreatic tumor cells in nude mice. Interestingly, 
the expression levels of Mpp6 were unaffected by the presence or absence of Saa3 in 
tumor cells, suggesting that the functional relationship between Saa3 and Mpp6 might be 
limited to CAFs. Understanding the molecular pathways implicated in the inhibitory role 
of Mpp6 on the pro-tumorigenic effect of CAFs should unveil novel therapeutic 
opportunities (Fig 38).  
 
 
 
Figure 38. Summary of CAFs and Saa3 characterization in PDAC mouse model. The 
scheme depicts our hypothesis: to reprogram tumor promoting CAFs into a more 
protective phenotype, similar to tumor suppressing NPFs. CAFs overexpress Saa3. Saa3 
null PDAC mice display stroma remodeling, migratory but not proliferative tumor cells 
and more importantly, tumor suppressing phenotype of CAFs mediated by Mpp6 
activation. Vertical arrows indicate upregulation of genes (Saa3, Mpp6). 
5.3 SAA1 in human PDAC 
Finally, we have interrogated whether our observations in GEM PDAC tumor 
models could be translated to the human scenario. As indicated above, the SAA3 locus is 
a non-expressed pseudogene (183, 184). On the other hand, the acute-phase SAA1 protein 
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has structural and functional characteristics that closely resemble those of murine Saa3, 
suggesting that SAA1 and Saa3 could be orthologue proteins.  
Indeed, SAA1 is overexpressed in human CAFs compared to NPFs. Moreover, high 
levels of SAA1 expression in the stromal component of human PDAC tumors correlate 
with significantly worse survival regardless of whether the tumor samples contain 
“normal” or “activated” stroma. However, high SAA1 expression in tumor samples with 
low stroma content also correlate with slightly increased survival, suggesting that SAA1 
may have a pro-tumorigenic effect when is highly expressed in stroma, but a possible 
anti-tumorigenic effect when overexpressed in tumor cells. A dual role for SAA proteins 
depending on cellular context has already been reported by other investigators (180, 198). 
In addition, it was described in a recent study that polymorphic variants of SAA1 could 
be the responsible for the different tumor promoting and suppressing functions. Out of 
the five SAA1 polymorphic allele, SAA1.1 and SAA1.3 possessed anti-angiogenic 
properties, whereas SAA1.5 lacked tumor suppressive effect (196). Of note, these 
polymorphic variants were not identified in mice (197), suggesting distinct regulatory 
processes of SAA levels in human and mice. Studying the functional relevance of the 
SAA1 variants in different cell populations of the tumor could shed light on the dual 
properties of this protein.  
Finally, MPP6 levels inversely correlated with SAA1 expression in human PDAC 
samples. Therefore, our results support the concept that murine Saa3 may serve as a 
model to study the role of the human acute-phase SAA1 protein in pancreatic cancer and 
to develop novel therapeutic strategies against this potential target. Since SAA1 is a 
secreted protein, it is conceivable that its pro-tumorigenic properties could be dwarfed 
with specific monoclonal antibodies providing that they are primarily delivered to the 
desmoplastic stroma, trying to avoid as much as possible their interaction with the tumor 
cells. In addition, a better understanding of the signaling pathways driven by SAA1 
should provide clues about differential signaling mechanisms in stromal versus tumor 
cells.  
Despite all the efforts invested in preclinical and clinical studies to find efficient 
treatment PDAC remains an incurable disease with slowly progressing therapeutic 
advances. Therefore, it is very important to search for novel strategies based on studies 
focusing on PDAC pathobiology that could help to design therapeutic approaches and 
could also be considered for the process of precision medicine.  
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6 Conclusions 
 
1. Cancer Associated Fibroblasts (CAFs) represent a heterogeneous population of 
fibroblasts in PDAC. PDGFRα+ subpopulation of CAFs display strong 
inflammatory signature with particular emphasis on innate immune response, 
cytokine and competent cascade signaling compared to PDGFRα+ normal 
pancreatic fibroblasts (NPFs).  
2. PDGFRα+ CAFs are pro-tumorigenic, while PDGFRα+ NPFs are tumor 
inhibitory when co-injected subcutaneously with mouse pancreatic tumor cells 
into nude mice and in co-culture in vitro studies with organoids. 
3. Comparative transcriptional profiling of PDGFRα+ CAFs identified Saa3 as the 
top upregulated gene and shRNA mediated functional validation qualified it as a 
potential target in CAFs.  
4. Other candidate genes, like Haptoglobin, Lumican, Has1 and Mesothelin were 
chosen for in vivo studies since they fulfill our criteria of target selection: 
overexpression in CAFs, low expression in NPFs, functional and human relevance 
in PDAC. Knock-out alleles of these gene have been incorporated in the 
therapeutic PDAC strain by CRISPR/Cas9 gene editing strategy: single Has1 
knockout and the triple combination of Haptoglobin, Lumican and Mesothelin. 
5. Germline elimination of Saa3 in a PDAC mouse strain does not seem to affect 
tumor development, as reflected by the same number and type of PanIN lesions 
present induced by the K-Ras oncogene in the context of p53 activity and by the 
lack of significant survival difference in mice that develop PDAC in a p53 
deficient background. However, tumors lacking Saa3 exhibit an undifferentiated 
phenotype. 
6. Saa3 elimination induces stroma remodeling, namely: extracellular matrix 
reorganization, vessel density increase and macrophage infiltration. These stromal 
changes do not result in a significant therapeutic benefit when tumor-bearing mice 
are treated with the standard of care Gemcitabine alone or in combination with 
the macrophage depleting agent Clodronate, or VEGF blocking antibody. 
7. Saa3 is a mediator of the pro-tumorigenic properties of PDGFRα+ CAFs as shown 
by significant decrease in tumor growth when Saa3 null CAFs and Saa3 
expressing tumor cells are co-injected orthotopically in the pancreas of nude mice. 
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Same results were observed in co-culture with organoids in vitro. However, anti-
tumorigenic effect of Saa3 null CAFs is lost when tumor cells also lack Saa3 
expression.  
8. Anti-tumorigenic properties of Saa3 null CAFs are mediated by the upregulation 
of the tight junction protein membrane-associated guanylate kinases family 
member 6 (Mpp6) as revealed by the transcriptional profiling of Saa3 null and 
competent CAFs and validated by orthotopic tumor reconstruction experiments. 
Mpp6 silencing in Saa3 null CAFs restored their tumor growth supporting 
properties. 
9. Saa3 null tumor cells displayed migratory phenotype in vitro and in vivo, as 
illustrated by the high number of disseminated tumor cells in the liver of the 
PDAC mouse strain. Nonetheless, these tumor cells were unable to proliferate and 
form metastatic outgrowth.  
10. SAA1, the human orthologue of mouse Saa3, is overexpressed in PDAC samples 
and in human CAFs. Moreover, this overexpression correlates with significantly 
worse survival when pancreatic stroma signatures are transcriptionally separated. 
SAA1-MPP6 expression negatively correlates in human CAFs. Therefore, our 
PDAC mouse model can help to study therapeutic opportunities that could be 
translated to patients. 
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7 Summary 
 
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the presence of 
abundant desmoplastic stroma primarily composed of cancer associated fibroblasts 
(CAFs). It is generally accepted that CAFs stimulate tumor progression and might be 
implicated in drug resistance and immunosuppression. However, CAFs represent a 
heterogeneous population in the tumor microenvironment. Distinct subpopulations of 
CAFs could possess different pro- and anti-tumorigenic properties. Indeed, our results 
show that PDGFRα+ CAFs isolated from genetically engineered mouse PDAC tumors 
support tumor growth, whereas normal pancreatic fibroblasts (NPFs) have tumor 
inhibitory effect in an orthotopic model. Thus, we have compared the transcriptional 
profile of CAF subpopulations with that of NPFs to identify genes potentially implicated 
in their pro-tumorigenic properties. We describe several differentially expressed 
candidate genes for targeting CAFs, as well as their in vivo functional validation by RNAi 
silencing and by generation of distinct stromal knockout mouse models. We report, that 
the top upregulated gene, Saa3, a member of the Serum Amyloid A (SAA) family, is a 
key mediator of the pro-tumorigenic activity of PDGFRα+ subpopulation of CAFs. 
Whereas Saa3 competent CAFs stimulate the growth of tumor cells in an orthotopic 
model, Saa3 null CAFs inhibit tumor growth. Saa3 also plays a role in the cross-talk 
between CAFs and tumor cells. Ablation of Saa3 in pancreatic tumor cells makes them 
insensitive to the inhibitory effect of Saa3 null CAFs. As a consequence, germline 
ablation of Saa3 does not prevent PDAC development in mice. The pro-tumorigenic 
activity of Saa3 in CAFs is mediated by Mpp6, a member of the palmitoylated membrane 
protein subfamily of the peripheral membrane-associated guanylate kinases (MAGUK). 
Finally, we interrogated whether these observations could be translated to a human 
scenario. Indeed, SAA1, the orthologue of murine Saa3, is overexpressed in human CAFs. 
Moreover, high levels of SAA1 in the stromal component correlate with worse survival. 
These findings support the concept that selective inhibition of SAA1 in CAFs may 
provide potential therapeutic benefit to PDAC patients. In addition, further stroma-
knockout PDAC mouse models generated in this study could help to better understand 
the complex pathobiology of pancreatic cancer and to design novel therapeutic 
approaches.  
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    Összefoglalás 
 
A pancreas tumorok legnagyobb részét a ductalis adenocarcinoma (PDAC) alkotja, 
melyet hatalmas mennyiségű desmoplasticus stróma jellemez. A pancreas tumorok 
strómáját nagyrészt tumor-asszociált fibroblasztok (TAF) formálják. Általánosan 
elfogadott, hogy a strómális TAF-ok fontos szerepet játszanak a daganatok 
képződésében, a terápiás rezisztenciában és az immunszuppresszióban. Azonban a TAF-
ok a tumor mikrokörnyezet egy heterogén populációja, ahol különböző pro – és 
antitumorális tulajdonságokkal rendelkezhetnek.   Erdeményeink is ezt indokolják, mivel 
transzgénikus PDAC egérmodellből izolált TAF-ok tumor serkentő, míg normál pancreas 
fibroblasztok (NPF) tumor gátló hatásúnak bizonyultak. Ennek tükrében, TAF és NPF 
populációk transzkripciós összehasonlító analízisével olyan terápiás célpontokat 
vizsgáltunk, melyek fontos szerepet játszhatnak a TAF-ok protumorális tulajdonságainak 
kialakulásában. Több olyan overexpresszált gént azonosítottunk, melyek potenciális TAF 
targetként szolgálhatnak, valamint ezeket in vivo funkcionálisan is validáltuk különböző 
egérmodellek segítségével. A legjelentősebben upregulált génnek az Saa3, a Serum 
Amyloid A (SAA) család tagja mutatkozott, amely eredményeink alapján kulcsszerepet 
játszik a PDGFRα+ TAF-ok szubpopulációjának pro-tumorális aktivitásában. Míg az 
Saa3-at expresszáló TAF-ok serkentik, az Saa3 null TAF-ok gátolják a tumor 
növekedését ortotopikus modellben. Ugyanakkor, az Saa3 fehérje, tumor sejt – 
fibroblaszt interakció mechanizmusában betöltött szerepét az is mutatja, hogy az Saa3 
null tumor sejtek érzéketlenné válnak az Saa3 null TAF-ok növekedés gátló hatásával 
szemben. Ennek következtében az Saa3 null állatokban nem gátolt a pancreas tumorok 
progressziója. TAF-okban viszont, az Saa3 protumorális aktivitását az Mpp6, a perifériás 
membránhoz kapcsolódó guanilát-kinázok (MAGUK) tagja közvetíti. Végül 
megfigyeléseink felhasználhatóságát humán pancreas daganatokban is vizsgáltuk, ahol 
az Saa3 humán ortológja, az SAA1 valóban overexpresszált tumor és TAF mintákban. 
Ezen felül, az SAA1 emelkedett szintje a PDAC strómában rosszabb túléléssel korrelál. 
Ez alapján elképzelhető, hogy az SAA1 szelektív gátlása TAF-okban potencialis terápiás 
előnyökkel járhat pancreas tumoros betegek számára. Emellett, a további TAF 
célpontokra létrehozott knockout egérmodelljeink tanulmányozása nagymértékben 
hozzájárulhat új, hatékonyabb terápiák kifejlesztéséhez.  
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